reserpine has been researched along with Disease Models, Animal in 298 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This review highlights the potential therapeutic approaches identified in studies that used reserpine-induced myalgia (RIM) animal model that exhibits nociplastic pain-associated phenotypes." | 9.22 | Therapeutic Approaches to Nociplastic Pain Based on Findings in the Reserpine-Induced Fibromyalgia-Like Animal Model. ( Nagakura, Y, 2022) |
| " Mechanical hyperalgesia, thermal allodynia, depressive- and anxious-related behavior, and locomotor activity were evaluated after reserpine (0." | 8.12 | Broad-spectrum cannabis oil ameliorates reserpine-induced fibromyalgia model in mice. ( Baldasso, GM; Capasso, R; Cicco, P; de Assis, PM; Dutra, RC; Ferrarini, EG; Gouvêa, MC; Moreira, ELG; Paes, RS; Raposo, NRB, 2022) |
| " This study aimed to evaluate the anti-depressant effect of Cerebrolysin (CBL) in Reserpine-induced depressed rats, its effect on oxidative stress, inflammation, regulatory cyclic AMP-dependent response element binding protein (CREB)/brain derived neurotropic factor (BDNF) signaling pathways, brain monoamines and histopathological changes was assessed." | 8.02 | Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence. ( Ahmed-Farid, OA; El Awdan, SA; El-Marasy, SA; Hassan, A; Ogaly, HA, 2021) |
| "The main study objective was to examine the role of pregabalin in depressive symptomatology comorbid to chronic widespread pain using a reserpine-induced myalgia model." | 7.96 | Chronic Pregabalin Treatment Ameliorates Pain, but not Depressive-Like Behaviors, in a Reserpine-Induced Myalgia Model in Rats. ( Alfosea-Cuadrado, GM; Blasco-Serra, A; Gonzalez-Soler, EM; Igual-Lopez, M; Orduna-Valls, J; Tornero-Tornero, C; Valverde-Navarro, AA, 2020) |
| "Reserpine treatment in rodents has been shown to induce depression-like behaviors that mimic monoamine dysfunction implicated in the development of depression." | 7.91 | BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1. ( Chen, Z; Lv, D; Shen, M; Wang, C; Yu, H; Zhang, Y; Zhou, D, 2019) |
| "Present study was designed to monitor the cognitive profile of the animals upon repeated administration of reserpine, so as to determine that whether these animals should be used as animal models of Parkinson's dementia." | 7.91 | Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. ( Haleem, DJ; Ikram, H, 2019) |
| "A new (aryloxyalkyl)adenine derivative Adeprophen (9-[2-(4-isopropylphenoxy)ethyl]adenine, VMA-99-82) has a strong antidepressant effect on the model of reserpine-induced depression in rats (single dose 4 mg/kg, intraperitoneally)." | 7.83 | Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats. ( Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN, 2016) |
| " Here, we investigated the relationship between SERT occupancies and the analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine, which are both 5-HT and NE reuptake inhibitors (SNRIs), on muscular pain in reserpine-induced myalgia (RIM) rats, an animal model of FM-like chronic pain." | 7.81 | Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats. ( Aoki, T; Fushiki, H; Honda, S; Irie, M; Iwashita, A; Murai, N; Murakami, Y; Nagakura, Y; Tamura, S, 2015) |
| "The reserpine-induced myalgia (RIM) rat manifests fibromyalgia-like chronic pain symptoms." | 7.78 | Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats. ( Nagakura, Y; Noto, T; Oe, T; Sekizawa, T; Shimizu, Y; Takahashi, M; Tamaki, K; Yoshimi, E, 2012) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 7.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "The effects of acute systemic administration of duloxetine, amitriptyline, mirtazapine and fluoxetine were compared in experimental models of gastric ulcer in rats." | 7.78 | Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats. ( Fan, DS; Guo, L; Ji, CX; Li, W; Liang, ZL; Xu, RM; Zhang, JJ, 2012) |
| "), potentiated the 5-hydroxytryptophan (5-HTP)-induced head twitch responses in mice and antagonized the reserpine-induced hypothermia in rats." | 7.77 | Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - an investigation using behavioral tests battery of depression. ( Bhatt, S; Gautam, B; Jindal, A; Mahesh, R; Pandey, D, 2011) |
| "p injection of reserpine for 15 days to establish the animal model of depression." | 7.77 | Nicotine restores monoamine neurotransmitter changes in the cortex and hippocampus of reserpinized rats as a model of depression. ( El-Shamy, KA; Khadrawy, YA; Mohamed, SI, 2011) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "The influence of (+/-)-verapamil and hydralazine on stress- and various chemically-induced gastric ulcers in rats together with their influence on various biochemical parameters which affect the development of the induced ulcers was examined." | 7.69 | Effect of (+/-)-verapamil and hydralazine on stress- and chemically-induced gastric ulcers in rats. ( al-Bekairi, AM; al-Rajhi, AM; Tariq, M, 1994) |
| "The mechanisms of digoxin-induced ventricular arrhythmias were studied in vivo using a novel experimental model." | 7.69 | Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. ( Hurt, CM; Pelleg, A; Xu, J, 1995) |
| "Two experimental animal models exhibiting functional and morphologic changes of exocrine glands similar to those seen in patients with cystic fibrosis (CF) have been reported in the rat: chronic stimulation with reserpine (Martinez et al." | 7.67 | Pulmonary function of the reserpine and isoproterenol models of cystic fibrosis. ( Boyd, RL; Fletcher, MT; Francis, EM; Mangos, JA, 1984) |
| "The chronically isoproterenol-treated rat has been proposed as an animal model for cystic fibrosis." | 7.67 | The chronically isoproterenol-treated rat in the study of cystic fibrosis: X-ray microanalysis of the submandibular gland. ( Müller, RM; Roomans, GM, 1984) |
| "The present investigation was undertaken to determine whether or not there are histochemical and morphological changes in the intestine of the chronically reserpine-treated rat, an animal model of cystic fibrosis." | 7.67 | Morphological and histochemical changes in intestinal mucosa in the reserpine-treated rat model of cystic fibrosis. ( Applegarth, DA; Owen, DA; Park, CM; Reid, PE; Sanker, JM, 1987) |
| "The choice of reserpine as practically the sole model substance used in research in depression over two decades was not dictated by rational considerations alone: hypothetical notions, prospects of the rapid realization of experimental research aims and the fascination of the exotic origin of this "natural" drug made a significant contribution." | 7.66 | Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression. ( Bein, HJ, 1978) |
| "The effects of cimetidine, a new histamine H2-receptor antagonist, on the development of experimental gastric and duodenal ulcers were studied." | 7.65 | Effects of cimetidine, a histamine H2-receptor antagonist, on various experimental gastric and duodenal ulcers. ( Okabe, S; Takagi, K; Takeuchi, K; Urushidani, T, 1977) |
| "Elevated calcium and protein concentration are a consistent abnormality in submaxillary saliva from patients with cystic fibrosis (CF) and from experimental animal models developed by the chronic administration of either isoproterenol (IPR) or reserpine." | 7.65 | The chronically reserpinized rat as a possible model for cystic fibrosis. VI. Synergistic effects of isoproterenol on Ca++ and protein in the submaxillary gland. ( Martinez, R; Wood, DL, 1977) |
| "Obesity is associated with low-grade chronic inflammation and oxidative stress, affecting the brain's reward system by decreasing dopaminergic neurotransmission." | 5.72 | Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease. ( Andrade, VM; Bitencourt, RM; Cavalheiro, EKFF; Cucker, L; da Silva, LE; Dal-Pizzol, F; Damiani, AP; Joaquim, L; Machado, RS; Magenis, ML; Michels, M; Oliveira, MP; Petronilho, F; Rezin, GT; Ribeiro, CB; Silva, MG; Tuon, T; Vilela, TC, 2022) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 5.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| "Daphnetin pretreatment attenuated the behavioral and biochemical changes induced by reserpine." | 5.62 | Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A. ( Bhatti, R; Kaur, A; Singh, AP; Singh, L, 2021) |
| "The reserpine-treated animals were subdivided into: Reserpine, Hesperetin (10 and 20 mg/kg), ECT and ECT+Hesperetin (10 and 20 mg/kg)." | 5.62 | Hesperetin ameliorates electroconvulsive therapy-induced memory impairment through regulation of hippocampal BDNF and oxidative stress in a rat model of depression. ( Alizadeh Makvandi, A; Amiri Moghaddam, S; Khalili, M; Roghani, M, 2021) |
| "The present study aims to evaluate the antidepressant effect of different formulations of Thymoquinone; free Thymoquinone (TQ), Thymoquinone-loaded Chitosan nanoparticles (TQ-TPP-Cs NPs) and Thymoquinone-loaded Chitosan nanoparticles coated with polysorbate 80 (TQ-TPP-Cs NPs-PSb80) that have been prepared to avoid the low bioavailability of TQ." | 5.56 | Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model. ( Abd Rabo, AA; Abd-El Daim, TM; Elfeky, AS; Fahmy, HM; Khadrawy, YA; Mostafa, IT; Mustafa, AB, 2020) |
| "Reserpine (1 mg/kg) was subcutaneously injected once daily for three consecutive days in male Swiss mice." | 5.56 | Relevance of Mitochondrial Dysfunction in the Reserpine-Induced Experimental Fibromyalgia Model. ( Brum, EDS; Dalla Corte, CL; Fialho, MFP; Fischer, SPM; Gonçalves, DF; Hartmann, DD; Machado-de-Ávila, RA; Oliveira, SM; Scussel, R; Soares, FAA, 2020) |
| "Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain and an extensive array of other symptoms including disordered sleep, fatigue, depression and anxiety." | 5.46 | Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats. ( Bonomini, F; Favero, G; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A; Trapletti, V, 2017) |
| "Chronic pain has consistently been correlated with depression." | 5.43 | Echinocystic acid reduces reserpine-induced pain/depression dyad in mice. ( Deng, YT; Feng, B; Han, J; Li, S; Wang, DS; Wang, XS; Yang, Q; Zhao, MG, 2016) |
| "Chronic widespread pain is a serious medical problem, yet the mechanisms of nociception and pain are poorly understood." | 5.42 | Peripheral and spinal mechanisms of nociception in a rat reserpine-induced pain model. ( Hayashi, K; Katanosaka, K; Kiyama, H; Mizumura, K; Taguchi, T; Wakatsuki, K; Yamanaka, A; Yamashita, M; Yasui, M, 2015) |
| "Gentiopicroside (Gent) is a secoiridoid compound isolated from Gentiana lutea that exhibits analgesic properties and inhibits the expression of GluN2B-containing N-methyl-D-aspartate (NMDA) receptors in the anterior cingulate cortex of mice." | 5.40 | Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice. ( Gao, GD; Guo, HJ; Li, XS; Liu, SB; Tian, Z; Zhang, N; Zhao, MG; Zhao, R, 2014) |
| "Reserpine treatment increased VCMs and decreased locomotor activity." | 5.39 | Effect of Hypericum perforatum on different models of movement disorders in rats. ( Athayde, ML; Boligon, AA; Busanello, A; Fachinetto, R; Leal, CQ; Reckziegel, P; Reis, EM; Röpke, J; Wagner, C, 2013) |
| " This review highlights the potential therapeutic approaches identified in studies that used reserpine-induced myalgia (RIM) animal model that exhibits nociplastic pain-associated phenotypes." | 5.22 | Therapeutic Approaches to Nociplastic Pain Based on Findings in the Reserpine-Induced Fibromyalgia-Like Animal Model. ( Nagakura, Y, 2022) |
| "This paper reviews recent research on the contribution of the proinflammatory cytokine interleukin-1 (IL- 1) and the purine nucleoside adenosine in mediating behavioral depression and related symptoms of conservation-withdrawal in animal models of both major depression and illness." | 4.86 | Biochemical and anatomical substrates of depression and sickness behavior. ( Furst, SJ; Hanff, TC; Minor, TR, 2010) |
| "By a combination of biochemical and pharmacodynamical analyses the author conducted a differentiated study of the role of separate neurohormones (adrenalin, noradrenalin, dopamine, serotonine) and their interconnection with other regulating systems (corticosteroids, nucleic acids) in the neurochemical structure of experimental models in depressive behaviour (reserpine depressions, depressions due to inhibitors of dopamine-beta-oxydase)." | 4.75 | [Catecholamines in the pathochemical structure of depressive conditions (according to material from a biological study)]. ( Baru, AM, 1975) |
| " Mechanical hyperalgesia, thermal allodynia, depressive- and anxious-related behavior, and locomotor activity were evaluated after reserpine (0." | 4.12 | Broad-spectrum cannabis oil ameliorates reserpine-induced fibromyalgia model in mice. ( Baldasso, GM; Capasso, R; Cicco, P; de Assis, PM; Dutra, RC; Ferrarini, EG; Gouvêa, MC; Moreira, ELG; Paes, RS; Raposo, NRB, 2022) |
| " This study aimed to evaluate the anti-depressant effect of Cerebrolysin (CBL) in Reserpine-induced depressed rats, its effect on oxidative stress, inflammation, regulatory cyclic AMP-dependent response element binding protein (CREB)/brain derived neurotropic factor (BDNF) signaling pathways, brain monoamines and histopathological changes was assessed." | 4.02 | Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence. ( Ahmed-Farid, OA; El Awdan, SA; El-Marasy, SA; Hassan, A; Ogaly, HA, 2021) |
| "To produce a fibromyalgia mouse model, wild-type mice were administered an intraperitoneal injection of reserpine once a day for three days, and two primary experiments were performed." | 3.96 | Excessive exercise induces cardiac arrhythmia in a young fibromyalgia mouse model. ( Doi, A; Nakata, T; Shin, MC; Uta, D; Yoshimura, M, 2020) |
| "The main study objective was to examine the role of pregabalin in depressive symptomatology comorbid to chronic widespread pain using a reserpine-induced myalgia model." | 3.96 | Chronic Pregabalin Treatment Ameliorates Pain, but not Depressive-Like Behaviors, in a Reserpine-Induced Myalgia Model in Rats. ( Alfosea-Cuadrado, GM; Blasco-Serra, A; Gonzalez-Soler, EM; Igual-Lopez, M; Orduna-Valls, J; Tornero-Tornero, C; Valverde-Navarro, AA, 2020) |
| "Reserpine treatment in rodents has been shown to induce depression-like behaviors that mimic monoamine dysfunction implicated in the development of depression." | 3.91 | BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1. ( Chen, Z; Lv, D; Shen, M; Wang, C; Yu, H; Zhang, Y; Zhou, D, 2019) |
| "Present study was designed to monitor the cognitive profile of the animals upon repeated administration of reserpine, so as to determine that whether these animals should be used as animal models of Parkinson's dementia." | 3.91 | Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. ( Haleem, DJ; Ikram, H, 2019) |
| " Animals were induced to a reserpine-induced depression model and were then chronically treated with duloxetine, desvenlafaxine or vehicle." | 3.85 | A standardization of the Novelty-Suppressed Feeding Test protocol in rats. ( Blasco-Serra, A; Cervera-Ferri, A; González-Soler, EM; Teruel-Martí, V; Valverde-Navarro, AA, 2017) |
| " Twenty four rats were divided into: control, rat model of depression induced by reserpine and depressive-like rats treated with Cannabis sativa extract (10mg/kg expressed as Δ9-tetrahydrocannabinol)." | 3.85 | Cannabis exacerbates depressive symptoms in rat model induced by reserpine. ( Abdel-Salam, OME; Hosny, EN; Khadrawy, YA; Sawie, HG, 2017) |
| " In this study we seek to determine ventilation and its responses to hypoxia in a reserpine--alpha-methyl-tyrosine model of parkinsonism in the rat." | 3.83 | Breathing in Parkinsonism in the Rat. ( Bialkowska, M; Boguszewski, P; Pokorski, M, 2016) |
| "A new (aryloxyalkyl)adenine derivative Adeprophen (9-[2-(4-isopropylphenoxy)ethyl]adenine, VMA-99-82) has a strong antidepressant effect on the model of reserpine-induced depression in rats (single dose 4 mg/kg, intraperitoneally)." | 3.83 | Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats. ( Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN, 2016) |
| " Here, we investigated the relationship between SERT occupancies and the analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine, which are both 5-HT and NE reuptake inhibitors (SNRIs), on muscular pain in reserpine-induced myalgia (RIM) rats, an animal model of FM-like chronic pain." | 3.81 | Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats. ( Aoki, T; Fushiki, H; Honda, S; Irie, M; Iwashita, A; Murai, N; Murakami, Y; Nagakura, Y; Tamura, S, 2015) |
| "This study investigated the effects of Phα1β, pregabalin and diclofenac using an animal model of fibromyalgia (FM)." | 3.80 | The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model. ( Castro, CJ; da Costa Lopes, AM; da Silva, CA; da Silva, JF; de Souza, AH; Ferreira, J; Gomez, MV; Klein, CP; Pereira, EM, 2014) |
| "More studies are still warranted in similar rodent models of pain and depression, so, that the present findings can be further substantiated to establish the clinical effectiveness of berberine in a subset of patients suffering from pain as well as depression." | 3.79 | Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model. ( Arora, V; Chopra, K, 2013) |
| "The reserpine-induced myalgia (RIM) rat manifests fibromyalgia-like chronic pain symptoms." | 3.78 | Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats. ( Nagakura, Y; Noto, T; Oe, T; Sekizawa, T; Shimizu, Y; Takahashi, M; Tamaki, K; Yoshimi, E, 2012) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 3.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "The effects of acute systemic administration of duloxetine, amitriptyline, mirtazapine and fluoxetine were compared in experimental models of gastric ulcer in rats." | 3.78 | Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats. ( Fan, DS; Guo, L; Ji, CX; Li, W; Liang, ZL; Xu, RM; Zhang, JJ, 2012) |
| "), potentiated the 5-hydroxytryptophan (5-HTP)-induced head twitch responses in mice and antagonized the reserpine-induced hypothermia in rats." | 3.77 | Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - an investigation using behavioral tests battery of depression. ( Bhatt, S; Gautam, B; Jindal, A; Mahesh, R; Pandey, D, 2011) |
| "p injection of reserpine for 15 days to establish the animal model of depression." | 3.77 | Nicotine restores monoamine neurotransmitter changes in the cortex and hippocampus of reserpinized rats as a model of depression. ( El-Shamy, KA; Khadrawy, YA; Mohamed, SI, 2011) |
| "Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in dopaminergic development." | 3.77 | Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. ( Aizawa, M; Iwakura, Y; Mizuno, M; Namba, H; Nawa, H; Shcherbakova, K; Sotoyama, H; Wang, R; Zheng, Y, 2011) |
| " A possible mechanism was explored in the test of antagonism of reserpine-induced ptosis and hypothermia in mice." | 3.76 | Antidepressant-like effect of genipin in mice. ( Chi, W; Cui, YL; Dong, TJ; Gao, S; Hu, LM; Liu, LP; Tian, JS, 2010) |
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "The effect of MXY to the mice's gastric ulcer induced by hydrochloric acid-ethanol, reserpine, and chronic gastric ulcer induced by acetic acid were observed." | 3.73 | [Study of the effect of exceed critical extracts from Radix Aucklandiae on experimental gastric ulcer model]. ( Han, J; Lin, H; Rong, X; Zhong, Z, 2005) |
| "The protective effect of a whey protein concentrate (WPC) was studied in three models of stomach ulcerative lesions induction: subcutaneous injection of indomethacin, and stress induced by either intraperitoneal injection of reserpine, or immobilization and holding in the cold (4 degrees C, 2 hours)." | 3.72 | Protective effect of bovine milk whey protein concentrate on the ulcerative lesions caused by subcutaneous administration of indomethacin. ( Antônio, MA; Bighetti, AE; Carvalho, JE; Rosaneli, CF; Sgarbieri, VC, 2004) |
| "The influence of (+/-)-verapamil and hydralazine on stress- and various chemically-induced gastric ulcers in rats together with their influence on various biochemical parameters which affect the development of the induced ulcers was examined." | 3.69 | Effect of (+/-)-verapamil and hydralazine on stress- and chemically-induced gastric ulcers in rats. ( al-Bekairi, AM; al-Rajhi, AM; Tariq, M, 1994) |
| "The mechanisms of digoxin-induced ventricular arrhythmias were studied in vivo using a novel experimental model." | 3.69 | Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. ( Hurt, CM; Pelleg, A; Xu, J, 1995) |
| "After chronic administration of propranolol (1 and 5 mg/kg, 14 days) to rats time-course of forced swimming changed with the decrease of rhythmical index of depression." | 3.68 | [The antidepressive properties of anaprilin]. ( Arushanian, EB; Beĭer, EV, 1992) |
| "Chronic reserpine treatment of animals, an experimental model for cystic fibrosis (CF), results in generalized exocrinopathy, impaired secretion, and decreased pancreatic content of amylase." | 3.68 | Alterations of amylase secretion in the chronically reserpinized rat: an acetylcholine-mediated phenomenon. ( Benrezzak, O; Bérubé, FL; Morisset, J, 1991) |
| " A recent clinical report, however, suggested that intraarterial injection of reserpine was affective in limiting tissue necrosis." | 3.68 | The role of intraarterial vasodilators in the treatment of inadvertent intraarterial injection injuries. ( Crawford, CR; Terranova, WA, 1990) |
| "Two experimental animal models exhibiting functional and morphologic changes of exocrine glands similar to those seen in patients with cystic fibrosis (CF) have been reported in the rat: chronic stimulation with reserpine (Martinez et al." | 3.67 | Pulmonary function of the reserpine and isoproterenol models of cystic fibrosis. ( Boyd, RL; Fletcher, MT; Francis, EM; Mangos, JA, 1984) |
| "Trimipramine, a tricyclic antidepressant, significantly inhibited the development of experimental gastric ulcers induced by various methods like stress, drug (aspirin, reserpine) and Shay's pyloric ligation in an inbred strain of albino rats." | 3.67 | Antiulcer effects of trimipramine using various laboratory models. ( Aguwa, CN; Ramanujam, TR, 1984) |
| "The chronically isoproterenol-treated rat has been proposed as an animal model for cystic fibrosis." | 3.67 | The chronically isoproterenol-treated rat in the study of cystic fibrosis: X-ray microanalysis of the submandibular gland. ( Müller, RM; Roomans, GM, 1984) |
| "The chronically reserpine-treated rat, an experimental model for cystic fibrosis, exhibits generalized exocrinopathy, impaired pancreatic secretion, and decreased pancreatic amylase." | 3.67 | Effects of malnutrition and chronic reserpine treatment on pancreatic exocrine function. ( Brannon, PM; Hazlett, D; Korc, M, 1986) |
| "The effects of reserpine injections were studied on the morphology of the pancreas in an experimental model for cystic fibrosis, the chronically reserpinized rat." | 3.67 | Light and electron microscopy of the exocrine pancreas in the chronically reserpinized rat. ( Grondin, G; LeBel, D; Leblond, FA; Morisset, J, 1989) |
| "Elemental distribution and ultrastructure of the submandibular gland, the parotid gland and the pancreas were investigated in three suggested animal models of the disease cystic fibrosis: the chronically reserpinized rat, the chronically isoproterenol-treated rat, and the chronically pilocarpine-treated rat." | 3.67 | X-ray microanalysis of exocrine glands in animal models for cystic fibrosis. ( Müller, RM; Roomans, GM, 1985) |
| "Reserpine treatment in rats induces morphological and functional disturbances in exocrine glands which resemble those produced by cystic fibrosis." | 3.67 | Reserpine treatment increases viscosity of fluid in the epididymis of rats. ( Wen, RQ; Wong, PY, 1988) |
| "Chronic treatment of rats with reserpine, isoproterenol, or a combination of these two agents has been suggested as a means to produce an experimental animal model for the chronic exocrinopathy cystic fibrosis." | 3.67 | Changes in glycoconjugates in rat submandibular gland after chronic treatment with reserpine and isoproterenol. ( Maltarello, MC; Müller, RM; Roomans, GM; Versura, P, 1988) |
| "Since reserpine precipitates depression in some hypertensive patients, we tested this drug on our animal model of depression." | 3.67 | Potentiated 5-hydroxytryptophan induced response suppression in rats following chronic reserpine. ( Aprison, MH; Brugge, KL; Hingtgen, JN, 1987) |
| "The present investigation was undertaken to determine whether or not there are histochemical and morphological changes in the intestine of the chronically reserpine-treated rat, an animal model of cystic fibrosis." | 3.67 | Morphological and histochemical changes in intestinal mucosa in the reserpine-treated rat model of cystic fibrosis. ( Applegarth, DA; Owen, DA; Park, CM; Reid, PE; Sanker, JM, 1987) |
| "The choice of reserpine as practically the sole model substance used in research in depression over two decades was not dictated by rational considerations alone: hypothetical notions, prospects of the rapid realization of experimental research aims and the fascination of the exotic origin of this "natural" drug made a significant contribution." | 3.66 | Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression. ( Bein, HJ, 1978) |
| "The effects of cimetidine, a new histamine H2-receptor antagonist, on the development of experimental gastric and duodenal ulcers were studied." | 3.65 | Effects of cimetidine, a histamine H2-receptor antagonist, on various experimental gastric and duodenal ulcers. ( Okabe, S; Takagi, K; Takeuchi, K; Urushidani, T, 1977) |
| "Rats treated for 7 days with reserpine develop structural changes in the submaxillary gland that resemble those that have been reported in cystic fibrosis." | 3.65 | The chronically reserpinized rat as a possible model for cystic fibrosis. I. Submaxillary gland morphology and ultrastructure. ( Adelstein, E; Barbero, GJ; Martinez, JR; Quissel, D, 1975) |
| "Elevated calcium and protein concentration are a consistent abnormality in submaxillary saliva from patients with cystic fibrosis (CF) and from experimental animal models developed by the chronic administration of either isoproterenol (IPR) or reserpine." | 3.65 | The chronically reserpinized rat as a possible model for cystic fibrosis. VI. Synergistic effects of isoproterenol on Ca++ and protein in the submaxillary gland. ( Martinez, R; Wood, DL, 1977) |
| "Submaxillary saliva from reserpine-treated rats was found to have alterations in composition similar to those reported in the same secretion from patients with cystic fibrosis." | 3.65 | The chronically reserpinized rat as a possible model for cystic fibrosis. II. Comparison and cilioinhibitory effects of submaxillary saliva. ( Adshead, PC; Barbero, GJ; Martinez, JR; Quissell, DO, 1975) |
| "The reserpine model was critical to the understanding of the role of monoamine system in the regulation of motor and affective disorders, as well as the efficacy of current PD treatments, such as L-DOPA and dopamine agonists." | 2.52 | Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model. ( Leão, AH; Ribeiro, AM; Santos, JR; Sarmento-Silva, AJ; Silva, RH, 2015) |
| "The development of efficient models for psychiatric diseases is complicated since the mechanisms of the disorders are not clear, major parts of the diagnosis depend on verbal communication with the patient and many of the symptoms are expressed mainly through the subjective experiences of the afflicted individual." | 2.41 | [Animal models of psychiatric diseases: possibilities, limitations, examples and demonstration of use]. ( Belmaker, RH; Einat, H, 2001) |
| "Depression is a leading cause of disability worldwide and the psychiatric diagnosis most commonly associated with suicide." | 1.91 | Antidepressant effect of 4-Butyl-alpha-agarofuran via HPA axis and serotonin system. ( Chen, Q; Hu, J; Lan, J; Li, X; Liu, M; Peng, Y; Shang, N; Wang, H; Xiang, L; Xiao, Q; Yin, D, 2023) |
| " This study evaluated the effect of chronic administration of testosterone propionate (TP) on motor behavior and neurochemical parameters in the reserpine-induced rat model of parkinsonism." | 1.72 | Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease. ( Bispo, JMM; Franco, HS; Gois, AM; Leal, PC; Lins, LCRF; Medeiros, KAAL; Melo, JEC; Ribeiro, AM; Santos, JR; Silva, RH; Silva, RS; Souza, MF, 2022) |
| "Obesity is associated with low-grade chronic inflammation and oxidative stress, affecting the brain's reward system by decreasing dopaminergic neurotransmission." | 1.72 | Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease. ( Andrade, VM; Bitencourt, RM; Cavalheiro, EKFF; Cucker, L; da Silva, LE; Dal-Pizzol, F; Damiani, AP; Joaquim, L; Machado, RS; Magenis, ML; Michels, M; Oliveira, MP; Petronilho, F; Rezin, GT; Ribeiro, CB; Silva, MG; Tuon, T; Vilela, TC, 2022) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 1.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| "Depression is the most frequent affective disorder and is the leading cause of disability worldwide." | 1.62 | A Reliable High-Throughput Screening Model for Antidepressant. ( He, J; Lai, Y; Liu, Q; Qiao, C; Shang, J; Zhang, R; Zhong, H, 2021) |
| "Fibromyalgia is characterized by the amplification of central nervous system pain with concomitant fatigue, sleep, mood disorders, depression, and anxiety." | 1.62 | Phoneutria nigriventer Tx3-3 peptide toxin reduces fibromyalgia symptoms in mice. ( Antunes, FTT; Campos, MM; Correa, ÁP; de Oliveira, IB; de Souza, AH; do Nascimento Cordeiro, M; Gomez, MV; Klein, CP; Pedron, C; Rebelo, IN, 2021) |
| "Fibromyalgia is a potentially disabling chronic disease, characterized by widespread pain and a range of comorbidities such as hypertension." | 1.62 | Inhibitors of angiotensin I converting enzyme potentiate fibromyalgia-like pain symptoms via kinin receptors in mice. ( Brusco, I; Justino, AB; Machado-de-Ávila, RA; Oliveira, SM; Scussel, R; Silva, CR, 2021) |
| "Daphnetin pretreatment attenuated the behavioral and biochemical changes induced by reserpine." | 1.62 | Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A. ( Bhatti, R; Kaur, A; Singh, AP; Singh, L, 2021) |
| "Reserpine caused hyperalgesia on the mechanical and thermal hyperalgesia on the 4th day was reverted by recombinant Phα1β (0." | 1.62 | Effects of intravenous administration of recombinant Phα1β toxin in a mouse model of fibromyalgia. ( Assis Ferreira, LC; Carvalho Dos Santos, D; Garcia Mendes, MP; Gomez, MV; José de Castro Junior, C; Rezende, MJS; Rigo, FK, 2021) |
| "Reserpine (RES) is an irreversible inhibitor of VMAT2 used to study Parkinson's disease (PD) and screening for antiparkinsonian treatments in rodents." | 1.62 | Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease. ( Abílio, VC; Conceição, IM; Freitas, TA; Izídio, GS; Leão, AHFF; Medeiros, AM; Meurer, YSR; Ribeiro, AM; Silva, RH, 2021) |
| "The reserpine-treated animals were subdivided into: Reserpine, Hesperetin (10 and 20 mg/kg), ECT and ECT+Hesperetin (10 and 20 mg/kg)." | 1.62 | Hesperetin ameliorates electroconvulsive therapy-induced memory impairment through regulation of hippocampal BDNF and oxidative stress in a rat model of depression. ( Alizadeh Makvandi, A; Amiri Moghaddam, S; Khalili, M; Roghani, M, 2021) |
| "The present study aims to evaluate the antidepressant effect of different formulations of Thymoquinone; free Thymoquinone (TQ), Thymoquinone-loaded Chitosan nanoparticles (TQ-TPP-Cs NPs) and Thymoquinone-loaded Chitosan nanoparticles coated with polysorbate 80 (TQ-TPP-Cs NPs-PSb80) that have been prepared to avoid the low bioavailability of TQ." | 1.56 | Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model. ( Abd Rabo, AA; Abd-El Daim, TM; Elfeky, AS; Fahmy, HM; Khadrawy, YA; Mostafa, IT; Mustafa, AB, 2020) |
| "Reserpine (1 mg/kg) was subcutaneously injected once daily for three consecutive days in male Swiss mice." | 1.56 | Relevance of Mitochondrial Dysfunction in the Reserpine-Induced Experimental Fibromyalgia Model. ( Brum, EDS; Dalla Corte, CL; Fialho, MFP; Fischer, SPM; Gonçalves, DF; Hartmann, DD; Machado-de-Ávila, RA; Oliveira, SM; Scussel, R; Soares, FAA, 2020) |
| "Fibromyalgia is a disease characterised as generalised chronic primary pain that causes functional disability and a reduction in patients' quality of life, without specific pathophysiology or appropriate treatment." | 1.51 | Kinins and their B ( Brusco, I; Cunha, TM; Ferreira, J; Fischer, S; Justino, AB; Machado-de-Ávila, RA; Oliveira, SM; Scussel, R; Silva, CR, 2019) |
| "Carvacrol (CA) is a phenolic monoterpene found in essential oils of many aromatic plants that presents antioxidant and neuroprotective effects." | 1.48 | Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine. ( Andrade, RAS; Bispo, JMM; Gois, AM; Lins, LCRF; Marchioro, M; Melo, TCS; Quintans-Junior, LJ; Ribeiro, AM; Santos, JR; Silva, RH; Souza, MF, 2018) |
| "Chronic pain and depressive disorders have been estimated to co-occur in up to 80% of patients and traditional antidepressants and analgesics have shown limited clinical efficacy." | 1.48 | α- (phenylselanyl) acetophenone mitigates reserpine-induced pain-depression dyad: Behavioral, biochemical and molecular docking evidences. ( Alves, D; Balaguez, R; Baldinotti, R; Birmann, PT; Brüning, CA; Fronza, MG; Savegnago, L; Sousa, FSS, 2018) |
| "Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain and an extensive array of other symptoms including disordered sleep, fatigue, depression and anxiety." | 1.46 | Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats. ( Bonomini, F; Favero, G; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A; Trapletti, V, 2017) |
| " Assessment of the effects of chronic administration of Diol (20mg/kg) and L-DOPA to animals with 6-OHDA-induced PS showed that administration of Diol alleviated the symptoms of sensorimotor deficit in right limbs in rats." | 1.46 | Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models. ( Ardashov, O; Ivanova, Е; Kapitsa, I; Khazanov, V; Salakhutdinov, N; Valdman, E; Volcho, K; Voronina, TI, 2017) |
| "Reserpine was toxic to worms (decreased the survival, food intake, development and changed egg laying and defecation cycles)." | 1.43 | Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans. ( Aschner, M; Caito, S; Chen, P; Fachinetto, R; Gubert, P; Reckziegel, P; Soares, FA, 2016) |
| "Hypertension was induced in uninephrectomized control rats (UNx) by subcutaneous implantation of a DOCA pellet plus administration of 1% NaCl in the drinking water (DOCA-salt) for 3 wk." | 1.43 | Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats. ( Cha, H; Cook, AK; Guan, Z; Inscho, EW; Pollock, DM; Pollock, JS; Singletary, ST; Van Beusecum, JP, 2016) |
| "Chronic pain has consistently been correlated with depression." | 1.43 | Echinocystic acid reduces reserpine-induced pain/depression dyad in mice. ( Deng, YT; Feng, B; Han, J; Li, S; Wang, DS; Wang, XS; Yang, Q; Zhao, MG, 2016) |
| "Reserpine (RES) has been reported to increase the brain's neural oxidative stress and cause cognitive dysfunction." | 1.43 | Nitric oxide pathway activity modulation alters the protective effects of (-)Epigallocatechin-3-gallate on reserpine-induced impairment in rats. ( Chang, KC; Chen, CN; Lin, RF; Shih, RL; Soung, HS; Tsai, CC; Tseng, HC; Wang, MH, 2016) |
| "Agmatine is an endogenous arginine metabolite that emerges as neuromodulator and a promising agent to manage diverse central nervous system disorders by modulating nitric oxide (NO) pathway, glutamate NMDA receptors and oxidative stress." | 1.43 | Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. ( Blum-Silva, CH; Colle, D; Cunha, AS; Cunha, MP; Farina, M; Matheus, FC; Moretti, M; Poli, A; Prediger, RD; Reginatto, FH; Rodrigues, AL; Sampaio, TB; Sandjo, LP; Santos, DB, 2016) |
| "Chronic widespread pain is a serious medical problem, yet the mechanisms of nociception and pain are poorly understood." | 1.42 | Peripheral and spinal mechanisms of nociception in a rat reserpine-induced pain model. ( Hayashi, K; Katanosaka, K; Kiyama, H; Mizumura, K; Taguchi, T; Wakatsuki, K; Yamanaka, A; Yamashita, M; Yasui, M, 2015) |
| "Reserpine treatment (1mg/kgs." | 1.42 | (-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. ( Chang, KC; Lin, RF; Soung, HS; Tsai, CC; Tseng, HC; Wang, MH, 2015) |
| "Gentiopicroside (Gent) is a secoiridoid compound isolated from Gentiana lutea that exhibits analgesic properties and inhibits the expression of GluN2B-containing N-methyl-D-aspartate (NMDA) receptors in the anterior cingulate cortex of mice." | 1.40 | Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice. ( Gao, GD; Guo, HJ; Li, XS; Liu, SB; Tian, Z; Zhang, N; Zhao, MG; Zhao, R, 2014) |
| "Reserpine treatment increased VCMs and decreased locomotor activity." | 1.39 | Effect of Hypericum perforatum on different models of movement disorders in rats. ( Athayde, ML; Boligon, AA; Busanello, A; Fachinetto, R; Leal, CQ; Reckziegel, P; Reis, EM; Röpke, J; Wagner, C, 2013) |
| " The stronger in vivo effect of (+)-catechin on L-DOPA methylation compared to the other dietary compounds is due to its better bioavailability in vivo." | 1.39 | Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. ( Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT, 2013) |
| "Gallic acid is a natural polyphenolic acid found in gall nuts, sumac, oak bark, tea leaves, grapes and wine, with potent antioxidant and antiapoptotic activity." | 1.39 | Gallic acid decreases vacuous chewing movements induced by reserpine in rats. ( Bürger, ME; de Freitas, CM; Fachinetto, R; Ferrari, MC; Peroza, LR; Reckziegel, P; Schaffer, LF, 2013) |
| "Pretreatment with clonidine or yohimbine failed to affect basal plasma corticosterone and ACTH concentrations, but abolished diazepam-induced inhibition of the HPA axis activity." | 1.38 | The involvement of noradrenergic mechanisms in the suppressive effects of diazepam on the hypothalamic-pituitary-adrenal axis activity in female rats. ( Muck-Šeler, D; Pivac, N; Švob Štrac, D, 2012) |
| "Here we used the animal models of extrapyramidal disorders cited above, which were performed in two distinct experiments: orofacial dyskinesia (OD)/catalepsy induced by acute reserpine and subchronic haloperidol after (experiment 1) and before (experiment 2) oral treatment with pecan shell aqueous extract (AE), a natural and promissory antioxidant." | 1.37 | Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. ( Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F, 2011) |
| "Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility." | 1.37 | Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. ( Gey van Pittius, NC; Grobbelaar, M; Hernandez-Pando, R; Jimenez, A; Leon, R; Louw, GE; McEvoy, CR; Murray, M; van Helden, PD; Victor, TC; Warren, RM, 2011) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Fragile X syndrome is caused by the functional loss of the fragile X mental retardation 1 (FMR1) gene." | 1.35 | Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. ( Bray, SM; Chang, S; He, C; Jin, P; Li, Z; Warren, ST; Zarnescu, DC, 2008) |
| "Berberine at lower dose did not affect the locomotor activity and barbiturate-induced sleep time." | 1.35 | On the mechanism of antidepressant-like action of berberine chloride. ( Dhir, A; Kulkarni, SK, 2008) |
| "Fibromyalgia is a prevalent and burdensome disorder characterized by chronic widespread pain and complex comorbid symptoms." | 1.35 | Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. ( Aoki, T; Matsuoka, N; Nagakura, Y; Oe, T, 2009) |
| "Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects." | 1.35 | Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats. ( Dwivedi, S; Kawale, LA; Nade, VS; Upasani, CD; Yadav, AV, 2009) |
| "In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain." | 1.34 | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. ( Brotchie, JM; Hallett, PJ, 2007) |
| "In models of Parkinson's disease, indirect-pathway eCB-LTD is absent but is rescued by a D2 receptor agonist or inhibitors of endocannabinoid degradation." | 1.34 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. ( Kreitzer, AC; Malenka, RC, 2007) |
| " Sea urchins use neurotransmitters as embryonic growth regulatory signals, so that adverse effects on neural substrates for mammalian brain development can be studied in this simple organism." | 1.34 | The sea urchin embryo, an invertebrate model for mammalian developmental neurotoxicity, reveals multiple neurotransmitter mechanisms for effects of chlorpyrifos: therapeutic interventions and a comparison with the monoamine depleter, reserpine. ( Bezuglov, VV; Buznikov, GA; Lauder, JM; Milosević, I; Nikitina, LA; Rakić, LM; Slotkin, TA, 2007) |
| "Reserpine (5 mg/kg) was administered three times a week for 12 weeks, and 18 h after each injection, arterial blood pressure (BP), heart rate, skin blood flow, plasma nitric oxide metabolites, plasma catecholamine levels, and behavioral parameters of a functional observational battery (FOB) were monitored." | 1.33 | Effects of 25 mT static magnetic field on blood pressure in reserpine-induced hypotensive Wistar-Kyoto rats. ( Masuda, H; Ohkubo, C; Okano, H, 2005) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| "Ropinirole was weakly neuroprotective in this model." | 1.32 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. ( Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L, 2004) |
| "Trihexyphenidyl (THP) is a drug commonly used to reduce parkinsonian symptoms." | 1.32 | Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats. ( Alvarez-Cervera, F; Arankowsky-Sandoval, G; Góngora-Alfaro, JL; Moo-Puc, RE; Villanueva-Toledo, J, 2004) |
| "Reserpine treatment caused a topographically organized reduction in CB1 receptor mRNA expression in the striatum (ranging from 11." | 1.31 | Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. ( Brotchie, JM; Crossman, AR; McGuire, S; McInnes, A; Silverdale, MA, 2001) |
| "The effects of a previous long-term administration of the mitochondrial toxin 3-nitropropionic acid were studied on an animal model of tardive dyskinesia, i." | 1.31 | The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. ( Abilio, VC; Araujo, CC; Bergamo, M; Calvente, PR; D'Almeida, V; Frussa, FR; Ribeiro, Rde A, 2002) |
| "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0." | 1.31 | Behavioral effects of MK-801 on reserpine-treated mice. ( Andreatini, R; Andreazza, AP; Dutra, RC; Tufik, S; Vital, MA, 2002) |
| "Reserpine treatment resulted in altered enzyme secretion from rat pancreatic acini in response to carbamylcholine and secretin (1,2)." | 1.29 | Alterations of pancreatic amylase secretion in the reserpinized rat model of cystic fibrosis. Effects of cerulein and EGF. ( Benrezzak, O; Bérubé, FL; Morisset, J; Vanier, M, 1994) |
| "Rats treated with reserpine develop spontaneous orofacial dyskinesia that has features similar to tardive dyskinesia (TD) in humans." | 1.29 | Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. ( Castañeda, E; Davis, DA; Neisewander, JL, 1994) |
| "Rats treated with reserpine for seven days revealed significantly lower values of plasma immunoreactive cationic trypsin (ogen) (39." | 1.29 | Plasma immunoreactive cationic trypsin(ogen) pattern in reserpinized rat model of cystic fibrosis. Resemblance to humans. ( Weizman, Z, 1996) |
| "Gastric ulcers were formed in pika that were subjected to water restraint for 4-5 days for 2 hours each day." | 1.28 | [Experimental stomach-ulcer on pika]. ( Horiuchi, S; Kodama, Y; Naito, K; Sakai, T, 1990) |
| "Experimental allergic encephalomyelitis (EAE), a T cell-mediated autoimmune disease can be transferred with lymphoid cells from actively immunized rats into naive recipients." | 1.28 | The role of mast cells in the elicitation of experimental allergic encephalomyelitis. ( Dietsch, GN; Hinrichs, DJ, 1989) |
| "Parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract." | 1.28 | Dopamine turnover and glutathione oxidation: implications for Parkinson disease. ( Cohen, G; Spina, MB, 1989) |
| "2." | 1.27 | Activation of brain function by S-135, a benzodiazepine receptor inverse agonist. ( Eigyo, M; Kawasaki, K; Matsubara, K; Matsushita, A; Shindo, H; Takada, S, 1988) |
| "Reserpine treatment led to surface alterations of Type I epithelial lung cells and diminished food uptake." | 1.27 | Clearance of Pseudomonas aeruginosa in different rat lung models. ( Dauner, HM; Döring, G, 1988) |
| "hipp seizure developed into motor seizure after establishing secondary epileptogenesis in AM and globys paliidus." | 1.26 | A study of psychomotor epilepsy with "kindled" cat preparations. ( Sato, M, 1976) |
| "The syndrome was not seen after thioridazine (3-7 mg/kg)." | 1.26 | Acute dystonia as an idiosyncratic response to neuroleptics in baboons. ( Anlezark, GM; Marsden, CD; Meldrum, BS, 1977) |
| "The treatment of both hyperlipidemia and hypertension appeared to be more effective than the treatment of hyperlipidemia, alone." | 1.26 | Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta. ( Hollander, W; Kirkpatrick, B; Madoff, I; Paddock, J, 1976) |
| "Reserpine-treated rats also showed a significant increase in the total protein recovered in the lung lavage fluid with a 233% increase in the absolute and relative amounts of a low molecular weight glycoprotein (15,000 mol wt)." | 1.26 | The chronically reserpinized rat as a possible animal model for cystic fibrosis. IV. The protein composition of pulmonary lavage fluid. ( Martinez, JR; Quissell, DO; Thompson, FE; Williams, CH, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 111 (37.25) | 18.7374 |
| 1990's | 25 (8.39) | 18.2507 |
| 2000's | 54 (18.12) | 29.6817 |
| 2010's | 78 (26.17) | 24.3611 |
| 2020's | 30 (10.07) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, S | 1 |
| Bray, SM | 1 |
| Li, Z | 1 |
| Zarnescu, DC | 1 |
| He, C | 1 |
| Jin, P | 1 |
| Warren, ST | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zhang, R | 1 |
| Qiao, C | 1 |
| Liu, Q | 1 |
| He, J | 1 |
| Lai, Y | 1 |
| Shang, J | 1 |
| Zhong, H | 1 |
| Song, JH | 1 |
| Won, SK | 1 |
| Eom, GH | 1 |
| Lee, DS | 1 |
| Park, BJ | 1 |
| Lee, JS | 1 |
| Son, CG | 1 |
| Park, JY | 1 |
| Nagakura, Y | 6 |
| Álvarez-Pérez, B | 2 |
| Deulofeu, M | 2 |
| Homs, J | 1 |
| Merlos, M | 2 |
| Vela, JM | 2 |
| Verdú, E | 2 |
| Boadas-Vaello, P | 2 |
| Beserra-Filho, JIA | 1 |
| Maria-Macêdo, A | 1 |
| Silva-Martins, S | 1 |
| Custódio-Silva, AC | 1 |
| Soares-Silva, B | 1 |
| Silva, SP | 1 |
| Lambertucci, RH | 1 |
| de Souza Araújo, AA | 1 |
| Lucchese, AM | 1 |
| Quintans-Júnior, LJ | 2 |
| Santos, JR | 9 |
| Silva, RH | 14 |
| Ribeiro, AM | 10 |
| Bispo, JMM | 6 |
| Melo, JEC | 3 |
| Gois, AM | 6 |
| Medeiros, KAAL | 3 |
| Silva, RS | 1 |
| Leal, PC | 4 |
| Franco, HS | 2 |
| Souza, MF | 5 |
| Lins, LCRF | 6 |
| Cavalheiro, EKFF | 1 |
| da Silva, LE | 1 |
| Oliveira, MP | 1 |
| Silva, MG | 1 |
| Damiani, AP | 1 |
| Ribeiro, CB | 1 |
| Magenis, ML | 1 |
| Cucker, L | 1 |
| Michels, M | 1 |
| Joaquim, L | 1 |
| Machado, RS | 1 |
| Vilela, TC | 1 |
| Bitencourt, RM | 1 |
| Andrade, VM | 1 |
| Dal-Pizzol, F | 1 |
| Petronilho, F | 1 |
| Tuon, T | 1 |
| Rezin, GT | 1 |
| Ferrarini, EG | 1 |
| Paes, RS | 1 |
| Baldasso, GM | 1 |
| de Assis, PM | 1 |
| Gouvêa, MC | 1 |
| Cicco, P | 1 |
| Raposo, NRB | 1 |
| Capasso, R | 1 |
| Moreira, ELG | 1 |
| Dutra, RC | 2 |
| Santos, TFO | 1 |
| Santos, RS | 1 |
| Monteiro, MCN | 1 |
| Mendonça, MS | 1 |
| Marchioro, M | 5 |
| Bagó-Mas, A | 1 |
| Tharwat, EK | 1 |
| Abdelaty, AO | 1 |
| Abdelrahman, AI | 1 |
| Elsaeed, H | 1 |
| Elgohary, A | 1 |
| El-Feky, AS | 1 |
| Ebrahim, YM | 1 |
| Sakraan, A | 1 |
| Ismail, HA | 1 |
| Khadrawy, YA | 4 |
| Aboul Ezz, HS | 1 |
| Noor, NA | 1 |
| Fahmy, HM | 2 |
| Mohammed, HS | 2 |
| Mohammed, FF | 1 |
| Radwan, NM | 1 |
| Ahmed, NA | 1 |
| da Cruz Guedes, E | 1 |
| Erustes, AG | 1 |
| Leão, AHFF | 2 |
| Carneiro, CA | 1 |
| Abílio, VC | 9 |
| Zuardi, AW | 1 |
| Hallak, JEC | 1 |
| Crippa, JA | 1 |
| Bincoletto, C | 1 |
| Smaili, SS | 1 |
| Reckziegel, P | 6 |
| Pereira, GJS | 1 |
| Wang, H | 2 |
| Hu, J | 2 |
| Chen, Q | 1 |
| Shang, N | 1 |
| Liu, M | 1 |
| Li, X | 2 |
| Xiang, L | 1 |
| Yin, D | 1 |
| Lan, J | 1 |
| Xiao, Q | 1 |
| Peng, Y | 1 |
| Oukhrib, M | 1 |
| Tamegart, L | 1 |
| Assafi, A | 1 |
| Hejji, L | 1 |
| Azzouz, A | 1 |
| Villarejo, LP | 1 |
| Haida, M | 1 |
| Mohamed, C | 1 |
| Gamrani, H | 2 |
| Qian, X | 1 |
| Zhong, Z | 2 |
| Lu, S | 1 |
| Zhang, Y | 3 |
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Miwa, M | 2 |
| Yoshida, M | 2 |
| Miura, R | 2 |
| Tanei, S | 1 |
| Tsuji, M | 1 |
| Takeda, H | 1 |
| Pereira, AG | 1 |
| Poli, A | 2 |
| Matheus, FC | 2 |
| de Bortoli da Silva, L | 1 |
| Fadanni, GP | 1 |
| Izídio, GS | 3 |
| Latini, A | 1 |
| Prediger, RD | 2 |
| Bakre, AG | 1 |
| Olayemi, JO | 1 |
| Ojo, OR | 1 |
| Odusanya, ST | 1 |
| Agu, GA | 1 |
| Aderibigbe, AO | 1 |
| Abd-El Daim, TM | 1 |
| Elfeky, AS | 1 |
| Abd Rabo, AA | 1 |
| Mustafa, AB | 1 |
| Mostafa, IT | 1 |
| Brum, EDS | 1 |
| Fialho, MFP | 1 |
| Fischer, SPM | 1 |
| Hartmann, DD | 1 |
| Gonçalves, DF | 1 |
| Scussel, R | 3 |
| Machado-de-Ávila, RA | 3 |
| Dalla Corte, CL | 1 |
| Soares, FAA | 1 |
| Oliveira, SM | 3 |
| Nakata, T | 1 |
| Doi, A | 1 |
| Uta, D | 1 |
| Yoshimura, M | 1 |
| Shin, MC | 1 |
| Pedron, C | 1 |
| Antunes, FTT | 1 |
| Rebelo, IN | 1 |
| Campos, MM | 1 |
| Correa, ÁP | 1 |
| Klein, CP | 2 |
| de Oliveira, IB | 1 |
| do Nascimento Cordeiro, M | 1 |
| Gomez, MV | 3 |
| de Souza, AH | 2 |
| Gonzalez-Soler, EM | 3 |
| Blasco-Serra, A | 3 |
| Alfosea-Cuadrado, GM | 1 |
| Igual-Lopez, M | 1 |
| Orduna-Valls, J | 1 |
| Tornero-Tornero, C | 1 |
| Valverde-Navarro, AA | 3 |
| El-Marasy, SA | 1 |
| El Awdan, SA | 1 |
| Hassan, A | 1 |
| Ahmed-Farid, OA | 1 |
| Ogaly, HA | 1 |
| Brusco, I | 2 |
| Justino, AB | 2 |
| Silva, CR | 2 |
| Cintra, RR | 1 |
| Melo, MS | 1 |
| Meurer, YSR | 2 |
| Singh, L | 1 |
| Kaur, A | 1 |
| Singh, AP | 1 |
| Bhatti, R | 1 |
| Garcia Mendes, MP | 1 |
| Carvalho Dos Santos, D | 1 |
| Rezende, MJS | 1 |
| Assis Ferreira, LC | 1 |
| Rigo, FK | 1 |
| José de Castro Junior, C | 1 |
| Jampolska, M | 1 |
| Andrzejewski, K | 1 |
| Zaremba, M | 1 |
| Joniec-Maciejak, I | 1 |
| Kaczyńska, K | 1 |
| Freitas, TA | 1 |
| Medeiros, AM | 2 |
| Conceição, IM | 1 |
| Alizadeh Makvandi, A | 1 |
| Khalili, M | 1 |
| Roghani, M | 1 |
| Amiri Moghaddam, S | 1 |
| Favero, G | 1 |
| Trapletti, V | 1 |
| Bonomini, F | 1 |
| Stacchiotti, A | 1 |
| Lavazza, A | 1 |
| Rodella, LF | 1 |
| Rezzani, R | 1 |
| Cervera-Ferri, A | 2 |
| Teruel-Martí, V | 2 |
| Valdman, E | 1 |
| Kapitsa, I | 1 |
| Ivanova, Е | 1 |
| Voronina, TI | 1 |
| Ardashov, O | 1 |
| Volcho, K | 1 |
| Khazanov, V | 1 |
| Salakhutdinov, N | 1 |
| Bruns, RF | 1 |
| Mitchell, SN | 1 |
| Wafford, KA | 1 |
| Harper, AJ | 1 |
| Shanks, EA | 1 |
| Carter, G | 1 |
| O'Neill, MJ | 1 |
| Murray, TK | 1 |
| Eastwood, BJ | 1 |
| Schaus, JM | 1 |
| Beck, JP | 1 |
| Hao, J | 1 |
| Witkin, JM | 1 |
| Chernet, E | 1 |
| Katner, JS | 1 |
| Ryder, JW | 1 |
| Masquelin, ME | 1 |
| Thompson, LK | 1 |
| Love, PL | 1 |
| Maren, DL | 1 |
| Falcone, JF | 1 |
| Menezes, MM | 1 |
| Zhang, L | 2 |
| Yang, CR | 1 |
| Svensson, KA | 1 |
| Hernandez-Leon, A | 1 |
| Fernández-Guasti, A | 1 |
| Martínez, A | 1 |
| Pellicer, F | 1 |
| González-Trujano, ME | 1 |
| Melo, TCS | 1 |
| Andrade, RAS | 1 |
| Soung, HS | 3 |
| Wang, MH | 3 |
| Chang, KC | 3 |
| Chen, CN | 2 |
| Chang, Y | 1 |
| Yang, CC | 1 |
| Tseng, HC | 3 |
| Amoateng, P | 1 |
| Kukuia, KKE | 1 |
| Mensah, JA | 1 |
| Osei-Safo, D | 1 |
| Adjei, S | 1 |
| Eklemet, AA | 1 |
| Vinyo, EA | 1 |
| Karikari, TK | 1 |
| Sousa, FSS | 1 |
| Birmann, PT | 1 |
| Baldinotti, R | 1 |
| Fronza, MG | 1 |
| Balaguez, R | 1 |
| Alves, D | 1 |
| Brüning, CA | 1 |
| Savegnago, L | 1 |
| Siemian, JN | 1 |
| Shang, L | 1 |
| Seaman, RW | 1 |
| Zhu, Q | 1 |
| Li, JX | 1 |
| Yu, H | 1 |
| Lv, D | 1 |
| Shen, M | 1 |
| Zhou, D | 1 |
| Chen, Z | 1 |
| Wang, C | 1 |
| Moore, C | 1 |
| Meshul, CK | 1 |
| Uchida, M | 1 |
| Kobayashi, O | 1 |
| Saito, H | 1 |
| Menezes, EC | 1 |
| Santos, PR | 1 |
| Goes, TC | 1 |
| Carvalho, VCB | 1 |
| Teixeira-Silva, F | 1 |
| Stevens, HE | 1 |
| Badauê-Passos, DJ | 1 |
| Ikram, H | 1 |
| Haleem, DJ | 1 |
| Draoui, A | 1 |
| El Hiba, O | 1 |
| Abdelaati, EK | 1 |
| Abbaoui, A | 1 |
| El Fari, R | 1 |
| Aitihya, M | 1 |
| Fischer, S | 1 |
| Cunha, TM | 1 |
| Ferreira, J | 2 |
| Xu, Y | 1 |
| Shao, T | 1 |
| Ruan, L | 1 |
| Wang, L | 1 |
| Sun, J | 1 |
| Li, J | 1 |
| Zhu, X | 1 |
| O'Donnell, JM | 1 |
| Pan, J | 1 |
| El-Ghazaly, MA | 1 |
| Sadik, NA | 1 |
| Rashed, ER | 1 |
| Abd-El-Fattah, AA | 1 |
| Reis, EM | 1 |
| Röpke, J | 1 |
| Busanello, A | 1 |
| Leal, CQ | 1 |
| Wagner, C | 2 |
| Boligon, AA | 2 |
| Athayde, ML | 2 |
| Fachinetto, R | 5 |
| Arora, V | 1 |
| Chopra, K | 1 |
| Konieczny, J | 2 |
| Lenda, T | 1 |
| Antkiewicz-Michaluk, L | 2 |
| Wąsik, A | 1 |
| Możdżeń, E | 1 |
| Romańska, I | 1 |
| Michaluk, J | 2 |
| da Costa Lopes, AM | 1 |
| Castro, CJ | 1 |
| Pereira, EM | 1 |
| da Silva, CA | 1 |
| da Silva, JF | 1 |
| Liu, SB | 1 |
| Zhao, R | 1 |
| Li, XS | 1 |
| Guo, HJ | 1 |
| Tian, Z | 1 |
| Zhang, N | 1 |
| Gao, GD | 1 |
| Zhao, MG | 2 |
| Tipton, AJ | 1 |
| Baban, B | 1 |
| Sullivan, JC | 1 |
| Minaiyan, M | 1 |
| Hajhashemi, V | 1 |
| Rabbani, M | 1 |
| Fattahian, E | 1 |
| Mahzouni, P | 1 |
| Chen, P | 1 |
| Caito, S | 1 |
| Gubert, P | 1 |
| Soares, FA | 1 |
| Aschner, M | 1 |
| Murai, N | 1 |
| Fushiki, H | 1 |
| Honda, S | 1 |
| Murakami, Y | 1 |
| Iwashita, A | 1 |
| Irie, M | 1 |
| Tamura, S | 1 |
| Aoki, T | 2 |
| Taguchi, T | 1 |
| Katanosaka, K | 1 |
| Yasui, M | 1 |
| Hayashi, K | 1 |
| Yamashita, M | 1 |
| Wakatsuki, K | 1 |
| Kiyama, H | 1 |
| Yamanaka, A | 1 |
| Mizumura, K | 1 |
| Lin, RF | 2 |
| Tsai, CC | 2 |
| Kronbauer, M | 1 |
| Segat, HJ | 2 |
| De David Antoniazzi, CT | 1 |
| Roversi, K | 2 |
| Pase, CS | 2 |
| Barcelos, RC | 3 |
| Burger, ME | 6 |
| Leão, AH | 2 |
| Sarmento-Silva, AJ | 1 |
| Dissel, S | 1 |
| Angadi, V | 1 |
| Kirszenblat, L | 1 |
| Suzuki, Y | 1 |
| Donlea, J | 1 |
| Klose, M | 1 |
| Koch, Z | 1 |
| English, D | 1 |
| Winsky-Sommerer, R | 1 |
| van Swinderen, B | 1 |
| Shaw, PJ | 1 |
| Ishimoto, T | 1 |
| Mano, H | 1 |
| Mori, H | 1 |
| Escrihuela-Vidal, F | 1 |
| Martínez-Expósito, F | 1 |
| Blasco-Ausina, MC | 1 |
| Martínez-Bellver, S | 1 |
| Bialkowska, M | 1 |
| Boguszewski, P | 1 |
| Pokorski, M | 1 |
| Guan, Z | 1 |
| Singletary, ST | 1 |
| Cha, H | 1 |
| Van Beusecum, JP | 1 |
| Cook, AK | 1 |
| Pollock, JS | 1 |
| Pollock, DM | 1 |
| Inscho, EW | 1 |
| Li, S | 1 |
| Han, J | 2 |
| Wang, DS | 1 |
| Feng, B | 1 |
| Deng, YT | 1 |
| Wang, XS | 1 |
| Yang, Q | 1 |
| Shih, RL | 1 |
| Ozerov, AA | 1 |
| Bagmetova, VV | 1 |
| Chernysheva, YV | 1 |
| Tyurenkov, IN | 1 |
| Cunha, AS | 1 |
| Moretti, M | 1 |
| Sampaio, TB | 1 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Cunha, MP | 1 |
| Blum-Silva, CH | 1 |
| Sandjo, LP | 1 |
| Reginatto, FH | 1 |
| Rodrigues, AL | 1 |
| Farina, M | 1 |
| Devadasan, C | 1 |
| Starr, B | 1 |
| Doyle, KM | 1 |
| Wells, JA | 1 |
| Shibata, S | 1 |
| Fujikawa, A | 1 |
| Takahashi, M | 2 |
| Saga, T | 1 |
| Aoki, I | 1 |
| Sawie, HG | 1 |
| Abdel-Salam, OME | 1 |
| Hosny, EN | 1 |
| Klanke, B | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Mao, Q | 1 |
| Huang, Z | 1 |
| Ip, S | 1 |
| Che, C | 1 |
| Kulkarni, SK | 3 |
| Dhir, A | 2 |
| Tanabe, M | 1 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Mao, QQ | 1 |
| Ip, SP | 1 |
| Tsai, SH | 1 |
| Che, CT | 1 |
| Thomas, DM | 2 |
| Francescutti-Verbeem, DM | 2 |
| Kuhn, DM | 2 |
| Slosberg, PS | 1 |
| Oe, T | 2 |
| Matsuoka, N | 1 |
| Sluka, KA | 1 |
| Nade, VS | 1 |
| Dwivedi, S | 1 |
| Kawale, LA | 1 |
| Upasani, CD | 1 |
| Yadav, AV | 1 |
| Gao, XL | 1 |
| Guo, WF | 1 |
| Li, RL | 2 |
| Chen, WW | 1 |
| Ghosh, B | 1 |
| Antonio, T | 1 |
| Zhen, J | 1 |
| Kharkar, P | 1 |
| Reith, ME | 1 |
| Dutta, AK | 1 |
| Ferger, B | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Okokon, JE | 1 |
| Antia, BS | 1 |
| Umoh, EE | 1 |
| Shah, A | 1 |
| Garzon-Muvdi, T | 1 |
| Mahajan, R | 1 |
| Duenas, VJ | 1 |
| Quiñones-Hinojosa, A | 1 |
| Alachkar, A | 1 |
| Brotchie, JM | 6 |
| Jones, OT | 1 |
| Tian, JS | 1 |
| Cui, YL | 1 |
| Hu, LM | 1 |
| Gao, S | 1 |
| Chi, W | 1 |
| Dong, TJ | 1 |
| Liu, LP | 1 |
| Hanff, TC | 1 |
| Furst, SJ | 1 |
| Minor, TR | 1 |
| Benvegnú, DM | 2 |
| Boufleur, N | 2 |
| Pase, C | 1 |
| Teixeira, AM | 1 |
| Emanuelli, T | 1 |
| da Rocha, JB | 1 |
| Malik, S | 1 |
| Kessar, SV | 1 |
| Singh, KN | 1 |
| Tozzi, A | 1 |
| de Iure, A | 1 |
| Di Filippo, M | 1 |
| Tantucci, M | 1 |
| Costa, C | 1 |
| Borsini, F | 1 |
| Ghiglieri, V | 1 |
| Giampà, C | 1 |
| Fusco, FR | 1 |
| Picconi, B | 1 |
| Calabresi, P | 1 |
| Trevizol, F | 1 |
| Dias, VT | 1 |
| Dolci, GS | 1 |
| Pereira, RP | 1 |
| de Souza Prestes, A | 1 |
| Sudati, JH | 1 |
| Morsch, VM | 1 |
| Rocha, JB | 4 |
| Louw, GE | 1 |
| Warren, RM | 1 |
| Gey van Pittius, NC | 1 |
| Leon, R | 1 |
| Jimenez, A | 1 |
| Hernandez-Pando, R | 1 |
| McEvoy, CR | 1 |
| Grobbelaar, M | 1 |
| Murray, M | 1 |
| van Helden, PD | 1 |
| Victor, TC | 1 |
| Mahesh, R | 1 |
| Jindal, A | 1 |
| Gautam, B | 1 |
| Bhatt, S | 1 |
| Pandey, D | 1 |
| Broadstock, M | 1 |
| Austin, PJ | 1 |
| Betts, MJ | 1 |
| Duty, S | 2 |
| El-Shamy, KA | 1 |
| Mohamed, SI | 1 |
| Noto, T | 1 |
| Sekizawa, T | 1 |
| Yoshimi, E | 1 |
| Tamaki, K | 1 |
| Shimizu, Y | 1 |
| Sotoyama, H | 1 |
| Zheng, Y | 1 |
| Iwakura, Y | 1 |
| Mizuno, M | 1 |
| Aizawa, M | 1 |
| Shcherbakova, K | 1 |
| Wang, R | 1 |
| Namba, H | 1 |
| Nawa, H | 1 |
| Sofue, T | 1 |
| Kiyomoto, H | 1 |
| Kobori, H | 1 |
| Urushihara, M | 1 |
| Nishijima, Y | 1 |
| Kaifu, K | 1 |
| Hara, T | 1 |
| Matsumoto, S | 1 |
| Ichimura, A | 1 |
| Ohsaki, H | 1 |
| Hitomi, H | 1 |
| Kawachi, H | 1 |
| Hayden, MR | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Ito, S | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 1 |
| Fernandes, VS | 1 |
| Melo, TG | 1 |
| Cabral, A | 1 |
| Ribeiro, RA | 1 |
| Hamada, N | 1 |
| Nishi, Y | 1 |
| Tajiri, Y | 1 |
| Setoyama, K | 1 |
| Kamimura, R | 1 |
| Miyahara, K | 1 |
| Nuruki, N | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Kojima, M | 1 |
| Mifune, H | 1 |
| Lima, MM | 1 |
| Andersen, ML | 1 |
| Reksidler, AB | 1 |
| Ferraz, AC | 1 |
| Vital, MA | 4 |
| Tufik, S | 2 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 2 |
| Niswender, CM | 1 |
| Švob Štrac, D | 1 |
| Muck-Šeler, D | 1 |
| Pivac, N | 1 |
| Chen, YL | 1 |
| Zhang, HT | 1 |
| Liu, J | 1 |
| Ji, CX | 1 |
| Fan, DS | 1 |
| Guo, L | 1 |
| Liang, ZL | 1 |
| Xu, RM | 1 |
| Zhang, JJ | 1 |
| Kang, KS | 1 |
| Yamabe, N | 1 |
| Wen, Y | 1 |
| Fukui, M | 1 |
| Zhu, BT | 1 |
| Peroza, LR | 1 |
| Schaffer, LF | 1 |
| Ferrari, MC | 1 |
| de Freitas, CM | 1 |
| Skalisz, LL | 1 |
| Beijamini, V | 1 |
| Joca, SL | 1 |
| Da Cunha, C | 1 |
| Andreatini, R | 2 |
| Xing, J | 1 |
| Yang, B | 1 |
| Dong, Y | 1 |
| Wang, B | 1 |
| Wang, J | 1 |
| Kallio, HP | 1 |
| Segovia, G | 1 |
| Mora, F | 1 |
| Crossman, AR | 3 |
| Araujo, CC | 2 |
| Bergamo, M | 2 |
| Calvente, PR | 2 |
| D'Almeida, V | 2 |
| Ribeiro, Rde A | 2 |
| Frussa-Filho, R | 7 |
| Alves, A | 2 |
| Callegari, L | 2 |
| Athayde, FR | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Carvalho, RC | 3 |
| Barbosa, PN | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 1 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Peixoto, MF | 1 |
| Guo, N | 1 |
| Hwang, DR | 1 |
| Lo, ES | 1 |
| Huang, YY | 1 |
| Laruelle, M | 1 |
| Abi-Dargham, A | 1 |
| Yaris, E | 1 |
| Kesim, M | 1 |
| Kadioglu, M | 1 |
| Kalyoncu, NI | 1 |
| Ulku, C | 1 |
| Ozyavuz, R | 1 |
| Valenti, O | 1 |
| Marino, MJ | 1 |
| Wittmann, M | 1 |
| Lis, E | 1 |
| DiLella, AG | 1 |
| Kinney, GG | 1 |
| Jain, S | 1 |
| Sharma, R | 1 |
| Millan, MJ | 1 |
| Di Cara, B | 1 |
| Hill, M | 1 |
| Jackson, M | 1 |
| Joyce, JN | 1 |
| Brotchie, J | 1 |
| McGuire, S | 2 |
| Crossman, A | 1 |
| Smith, L | 1 |
| Jenner, P | 4 |
| Gobert, A | 1 |
| Peglion, JL | 1 |
| Brocco, M | 1 |
| Nakao, N | 1 |
| Shintani-Mizushima, A | 1 |
| Kakishita, K | 1 |
| Itakura, T | 1 |
| Moo-Puc, RE | 1 |
| Villanueva-Toledo, J | 1 |
| Arankowsky-Sandoval, G | 1 |
| Alvarez-Cervera, F | 1 |
| Góngora-Alfaro, JL | 1 |
| Rosaneli, CF | 1 |
| Bighetti, AE | 2 |
| Antônio, MA | 2 |
| Carvalho, JE | 2 |
| Sgarbieri, VC | 1 |
| Araujo, NP | 1 |
| Pereira, RC | 1 |
| Gonzalez, C | 1 |
| Bellot, RG | 1 |
| Castro, JP | 1 |
| Fukushiro, DF | 1 |
| Rodrigues, MS | 1 |
| Chinen, CC | 1 |
| Burger, M | 1 |
| Calegari, L | 1 |
| Paixão, MW | 1 |
| Braga, AL | 1 |
| Okano, H | 1 |
| Masuda, H | 1 |
| Ohkubo, C | 1 |
| Fachineto, R | 1 |
| Kohn, LK | 1 |
| Rehder, VL | 1 |
| Foglio, MA | 1 |
| Possenti, A | 1 |
| Vilela, L | 1 |
| Lin, H | 1 |
| Rong, X | 1 |
| Patti, CC | 1 |
| Takatsu-Coleman, AL | 1 |
| Kameda, SR | 1 |
| Souza, CF | 1 |
| Garcez-do-Carmo, L | 1 |
| van der Elst, MC | 1 |
| Wunderink, YS | 1 |
| Ellenbroek, BA | 1 |
| Cools, AR | 1 |
| Hallett, PJ | 1 |
| Lebel, M | 1 |
| Rodrigue, ME | 1 |
| Agharazii, M | 1 |
| Larivière, R | 1 |
| Kreitzer, AC | 1 |
| Malenka, RC | 1 |
| Milioli, EM | 1 |
| Cologni, P | 1 |
| Santos, CC | 1 |
| Marcos, TD | 1 |
| Yunes, VM | 1 |
| Fernandes, MS | 1 |
| Schoenfelder, T | 1 |
| Costa-Campos, L | 1 |
| Buznikov, GA | 1 |
| Nikitina, LA | 1 |
| Rakić, LM | 1 |
| Milosević, I | 1 |
| Bezuglov, VV | 1 |
| Lauder, JM | 1 |
| Slotkin, TA | 1 |
| Urigüen, L | 1 |
| Arteta, D | 1 |
| Díez-Alarcia, R | 1 |
| Ferrer-Alcón, M | 1 |
| Díaz, A | 1 |
| Pazos, A | 1 |
| Meana, JJ | 1 |
| Ghia, JE | 1 |
| Blennerhassett, P | 1 |
| Collins, SM | 1 |
| Okada, M | 1 |
| Shimada, K | 1 |
| Martinez, JL | 1 |
| Jensen, RA | 1 |
| McGaugh, JL | 1 |
| Sethy, VH | 1 |
| Hodges, DH | 1 |
| Karmazyn, M | 1 |
| Beamish, RE | 1 |
| Dhalla, NS | 1 |
| Leonard, BE | 1 |
| Morton, D | 1 |
| Parker, A | 1 |
| Estrada, P | 1 |
| Martinez, JR | 8 |
| Kedem, J | 1 |
| Zurovski, Y | 1 |
| Miller, H | 1 |
| Battler, A | 1 |
| McCurdy, RE | 1 |
| Martinez, R | 2 |
| Kluger, J | 1 |
| Horner, H | 1 |
| Reidenberg, MM | 1 |
| Vardi, Y | 1 |
| Regev, I | 1 |
| Rosenbaum, M | 1 |
| Flechter, S | 1 |
| Roscher, AA | 1 |
| Wiesmann, UN | 1 |
| Honegger, UE | 1 |
| Willner, P | 1 |
| Vergona, RA | 1 |
| Herrott, C | 1 |
| Garippa, R | 1 |
| Hirkaler, G | 1 |
| Boyd, RL | 1 |
| Francis, EM | 1 |
| Fletcher, MT | 1 |
| Mangos, JA | 1 |
| Pack, SJ | 1 |
| Zamoshchina, TA | 1 |
| Saratikov, AS | 1 |
| Aguwa, CN | 2 |
| Ramanujam, TR | 1 |
| Forstner, J | 1 |
| Roomi, N | 1 |
| Fahim, R | 1 |
| Gall, G | 1 |
| Perdue, M | 1 |
| Forstner, G | 1 |
| Gershanik, O | 1 |
| Heikkila, RE | 2 |
| Duvoisin, RC | 4 |
| Bylund, DB | 1 |
| Mawhinney, T | 1 |
| Camden, J | 1 |
| Ray, G | 1 |
| Cooper, DR | 2 |
| Marrel, C | 2 |
| Testa, B | 2 |
| van de Waterbeemd, H | 2 |
| Quinn, N | 1 |
| Marsden, CD | 5 |
| Müller, RM | 3 |
| Roomans, GM | 4 |
| Atadzhanov, M | 1 |
| Zhang, SZ | 1 |
| Chen, XG | 1 |
| Jin, JS | 1 |
| Zhao, ZH | 1 |
| Yu, RC | 1 |
| Wen, ZY | 1 |
| Cao, XP | 1 |
| Zhao, RL | 1 |
| Wei, BH | 1 |
| Simpson, CF | 1 |
| Boucek, RJ | 1 |
| Shiffman, ML | 1 |
| Spitzer, RE | 1 |
| Swender, PT | 1 |
| Galey, WR | 1 |
| Johnels, B | 2 |
| Steg, G | 1 |
| Kehr, W | 1 |
| Freis, ED | 1 |
| Notargiacomo, A | 1 |
| Burris, JF | 1 |
| Mittal, GC | 1 |
| Mawhinney, TP | 1 |
| Feather, MS | 1 |
| Barbero, GJ | 3 |
| al-Bekairi, AM | 1 |
| al-Rajhi, AM | 1 |
| Tariq, M | 1 |
| Morisset, J | 4 |
| Bérubé, FL | 2 |
| Vanier, M | 1 |
| Benrezzak, O | 2 |
| al-Harbi, MM | 1 |
| Islam, MW | 1 |
| al-Shabanah, OA | 1 |
| al-Gharably, NM | 1 |
| Xu, J | 1 |
| Hurt, CM | 1 |
| Pelleg, A | 1 |
| Jovanović-Mićić, D | 1 |
| Samardzić, R | 1 |
| Beleslin, DB | 1 |
| Neisewander, JL | 1 |
| Castañeda, E | 1 |
| Davis, DA | 1 |
| László, F | 1 |
| Karácsony, G | 1 |
| Pávó, I | 1 |
| Varga, C | 1 |
| Rojik, I | 1 |
| László, FA | 1 |
| Lin, HC | 1 |
| Yu, PC | 1 |
| Lee, SD | 1 |
| Tsai, YT | 1 |
| Kuo, JS | 1 |
| Yang, MC | 1 |
| Weizman, Z | 1 |
| Maneuf, YP | 1 |
| Hille, CJ | 1 |
| Brooks, S | 1 |
| Kaur, S | 1 |
| Starr, BS | 1 |
| Starr, MS | 1 |
| Kato, M | 1 |
| Iwata, H | 1 |
| Katayama, T | 1 |
| Asai, H | 1 |
| Narita, H | 1 |
| Endo, T | 1 |
| Clementi, G | 1 |
| Caruso, A | 1 |
| Cutuli, VM | 1 |
| Prato, A | 1 |
| de Bernardis, E | 1 |
| Amico-Roxas, M | 1 |
| Palermo-Neto, J | 1 |
| Kinnamon, KE | 1 |
| Poon, BT | 1 |
| Hanson, WL | 1 |
| Waits, VB | 1 |
| Ossowska, K | 1 |
| Lorenc-Koci, E | 1 |
| Wolfarth, S | 1 |
| Tolwani, RJ | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Hill, MP | 1 |
| Queiroz, CM | 1 |
| Shafi, S | 1 |
| Stepanova, IP | 1 |
| Fitzsimmons, C | 1 |
| Bowyer, DE | 1 |
| Welzel, D | 1 |
| Born, GV | 1 |
| Silverdale, MA | 1 |
| McInnes, A | 1 |
| Einat, H | 1 |
| Belmaker, RH | 1 |
| Ishiguro, Y | 1 |
| Morgan, JP | 1 |
| Naidu, PS | 1 |
| El Yacoubi, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Bertorelli, R | 1 |
| Ongini, E | 1 |
| Costentin, J | 1 |
| Vaugeois, JM | 1 |
| Frussa, FR | 1 |
| Andreazza, AP | 1 |
| Le Pen, G | 1 |
| Moreau, JL | 1 |
| Varró, V | 1 |
| Sole, MJ | 1 |
| Wurtman, RJ | 1 |
| Lo, CM | 1 |
| Kamble, AB | 1 |
| Sonnenblick, EH | 1 |
| Okabe, S | 1 |
| Takeuchi, K | 1 |
| Urushidani, T | 1 |
| Takagi, K | 1 |
| Halbhübner, K | 1 |
| Herken, H | 1 |
| Loos, D | 1 |
| Sato, M | 1 |
| Schaub, RG | 1 |
| Meyers, KM | 1 |
| Sande, RD | 1 |
| Adelstein, E | 1 |
| Quissel, D | 1 |
| Bein, HJ | 1 |
| Zervas, NT | 2 |
| Wada, JA | 1 |
| Meldrum, BS | 1 |
| Anlezark, GM | 1 |
| Sordelli, DO | 1 |
| Cassino, RJ | 1 |
| Pivetta, OH | 1 |
| David, J | 2 |
| Kaul, CL | 2 |
| Grewal, RS | 2 |
| Perlmutter, J | 1 |
| Neuschl, J | 1 |
| Kohút, A | 1 |
| Nicák, A | 1 |
| Whitehill, R | 1 |
| Hakala, MW | 1 |
| Weihe, WH | 2 |
| Krejs, GJ | 1 |
| Beglinger, R | 2 |
| Blum, AL | 1 |
| Baru, AM | 1 |
| Poirier, LJ | 2 |
| Hollander, W | 1 |
| Madoff, I | 1 |
| Paddock, J | 1 |
| Kirkpatrick, B | 1 |
| Lazarus, HM | 1 |
| Hutto, W | 1 |
| Ellertson, DG | 1 |
| Wood, DL | 1 |
| Andén, NE | 1 |
| Thompson, FE | 1 |
| Quissell, DO | 2 |
| Williams, CH | 1 |
| Kogure, K | 1 |
| Scheinberg, P | 1 |
| Kishikawa, H | 1 |
| Busto, R | 1 |
| Reinmuth, OM | 1 |
| Adshead, PC | 1 |
| Hough, FS | 1 |
| Gevers, W | 1 |
| Snider, RL | 1 |
| Porter, JM | 1 |
| Parkes, JD | 1 |
| Pycock, C | 1 |
| Tarsy, D | 1 |
| Arushanian, EB | 1 |
| Beĭer, EV | 1 |
| Sonsalla, PK | 1 |
| Luchelli-Fortis, MA | 1 |
| Crawford, CR | 1 |
| Terranova, WA | 1 |
| Kodama, Y | 1 |
| Sakai, T | 1 |
| Naito, K | 1 |
| Horiuchi, S | 1 |
| Hazlett, D | 1 |
| Korc, M | 1 |
| Brannon, PM | 1 |
| Dietsch, GN | 1 |
| Hinrichs, DJ | 1 |
| Leblond, FA | 2 |
| LeBel, D | 2 |
| Grondin, G | 1 |
| Matsushita, A | 1 |
| Kawasaki, K | 1 |
| Matsubara, K | 1 |
| Eigyo, M | 1 |
| Shindo, H | 1 |
| Takada, S | 1 |
| Spina, MB | 1 |
| Cohen, G | 1 |
| Wen, RQ | 1 |
| Wong, PY | 1 |
| Vetulani, J | 1 |
| Rokosz-Pelc, A | 1 |
| Döring, G | 1 |
| Dauner, HM | 1 |
| de Yebenes, JG | 1 |
| Fahn, S | 1 |
| Jackson-Lewis, V | 1 |
| Jorge, P | 1 |
| Mena, MA | 1 |
| Reiriz, J | 1 |
| Martinez, AM | 1 |
| Versura, P | 1 |
| Maltarello, MC | 1 |
| Brugge, KL | 1 |
| Hingtgen, JN | 1 |
| Aprison, MH | 1 |
| Park, CM | 1 |
| Reid, PE | 1 |
| Owen, DA | 1 |
| Sanker, JM | 1 |
| Applegarth, DA | 1 |
| Baizman, ER | 1 |
| Ezrin, AM | 1 |
| Ferrari, RA | 1 |
| Luttinger, D | 1 |
| Angel, A | 1 |
| Wyllie, RG | 1 |
| Hill, GS | 1 |
| Murray, G | 1 |
| Ramsden, PW | 1 |
| Heptinstall, RH | 1 |
| Akiskal, HS | 1 |
| McKinney, WT | 1 |
| Greenberg, S | 1 |
| Engelbrecht, JA | 1 |
| Wilson, WR | 1 |
| Clasen, RA | 1 |
| Pandolfi, S | 1 |
| Casey, D | 1 |
| Hori, H | 1 |
| Rosoff, CB | 1 |
| Langelier, P | 1 |
| Bédard, P | 1 |
| Boucher, R | 1 |
| Larochelle, L | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Babington, RG | 1 |
| Wedeking, PW | 1 |
| Masek, K | 1 |
| Rasková, H | 1 |
| Rotta, J | 1 |
| Sakai, K | 1 |
| Sugano, S | 1 |
| Isono, C | 1 |
| Velkov, VA | 1 |
| Carlsson, A | 2 |
| Martin, L | 1 |
| Anton, AH | 1 |
| Tedeschi, DH | 1 |
| Boshek, RL | 1 |
| Boston, JE | 1 |
| Brossi, A | 1 |
| Pool, W | 1 |
| Sheppard, H | 1 |
| Burns, JJ | 1 |
| Kaiser, A | 1 |
| Bigler, R | 1 |
| Bartholini, G | 1 |
| Pletscher, A | 1 |
| Fog, R | 1 |
| Robertson, JT | 1 |
| Plotnikoff, NP | 1 |
| Kastin, AJ | 1 |
| Anderson, MS | 1 |
| Schally, AV | 1 |
| Von Koch, L | 1 |
| Fugua, JM | 1 |
| Kennedy, JH | 2 |
| Stickney, JL | 1 |
| Horst, WD | 1 |
| Pool, WR | 1 |
| Spiegel, HE | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Tret'iakova, KA | 1 |
| Samoĭlova, ZT | 1 |
| Osterholm, JL | 1 |
| Mathews, GJ | 1 |
| Irvin, JD | 1 |
| Calesnick, B | 1 |
| Lenfeld, J | 1 |
| Jezdinský, J | 1 |
| Marek, J | 1 |
| Kroutil, M | 1 |
| Wiedermann, D | 1 |
| Hromek, F | 1 |
| Vasků, J | 1 |
| Cídl, K | 1 |
| Mitova, M | 1 |
| Feola, M | 1 |
| Haiderer, O | 1 |
| Baum, T | 1 |
| Eckfeld, DK | 1 |
| Metz, N | 1 |
| Dinish, JL | 1 |
| Rowles, G | 1 |
| Van Pelt, R | 1 |
| Shropshire, AT | 1 |
| Fernandez, SP | 1 |
| Gluckman, MI | 1 |
| Bruce, WF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for reserpine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic Approaches to Nociplastic Pain Based on Findings in the Reserpine-Induced Fibromyalgia-Like Animal Model.
Topics: Animals; Chronic Pain; Disease Models, Animal; Fibromyalgia; Humans; Myalgia; Reserpine | 2022 |
Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Humans; Mental Disorders; Parkinson Di | 2015 |
Animal models of neurological disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Amyloid beta-Protein Precursor; Ani | 2010 |
Biochemical and anatomical substrates of depression and sickness behavior.
Topics: Adenosine; Adrenergic Uptake Inhibitors; Animals; Basal Ganglia; Brain; Depression; Disease Models, | 2010 |
Attenuation of experimentally-induced amnesia.
Topics: Adrenocorticotropic Hormone; alpha-Methyltyrosine; Amnesia; Amphetamine; Animals; Anisomycin; Cycloh | 1981 |
The validity of animal models of depression.
Topics: 5-Hydroxytryptophan; Amphetamine; Animals; Behavior, Animal; Circadian Rhythm; Depressive Disorder; | 1984 |
[Modeling parkinsonism (review)].
Topics: Aluminum; Animals; Carbachol; Cats; Caudate Nucleus; Chlorides; Chlorpromazine; Disease Models, Anim | 1982 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
[Animal models of psychiatric diseases: possibilities, limitations, examples and demonstration of use].
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Humans; Mental Disorder | 2001 |
Vasospasm: an update.
Topics: Angiotensin II; Animals; Blood; Cerebral Angiography; Cerebral Arteries; Diagnosis, Differential; Di | 1979 |
Pharmacological prophylaxis in the kindling model of epilepsy.
Topics: Amygdala; Anesthetics, Local; Animals; Antidepressive Agents, Tricyclic; Atropine; Aziridines; Carba | 1977 |
[Catecholamines in the pathochemical structure of depressive conditions (according to material from a biological study)].
Topics: Adrenal Cortex Hormones; Adrenal Medulla; Animals; Brain; Catecholamines; Cell Nucleus; Depression; | 1975 |
The MPTP-treated mouse as a model of parkinsonism: how good is it?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Eval | 1992 |
Depressive disorders: toward a unified hypothesis.
Topics: Age Factors; Animals; Anxiety, Separation; Behavior, Animal; Biogenic Amines; Conditioning, Operant; | 1973 |
Biochemical and pharmacological aspects of Parkinsonism.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Chemoreceptor Cells; Chlorpromazine; Co | 1972 |
On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats.
Topics: Amphetamine; Animals; Basal Ganglia; Caffeine; Catalepsy; Cocaine; Compulsive Behavior; Corpus Stria | 1972 |
Cerebral arterial spasm: current concepts.
Topics: Anesthesia, General; Animals; Blood Coagulation; Blood Platelets; Brain; Catecholamines; Cerebral Ar | 1974 |
1 trial available for reserpine and Disease Models, Animal
| Article | Year |
|---|---|
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transpla | 2004 |
280 other studies available for reserpine and Disease Models, Animal
| Article | Year |
|---|---|
Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.
Topics: Animals; Disease Models, Animal; Drosophila; Drosophila Proteins; Drug Evaluation, Preclinical; Fema | 2008 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
A Reliable High-Throughput Screening Model for Antidepressant.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Drug Evaluatio | 2021 |
Improvement Effects of Myelophil on Symptoms of Chronic Fatigue Syndrome in a Reserpine-Induced Mouse Model.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Behavior, Animal; Calcium-Binding Proteins; Corpus | 2021 |
Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition.
Topics: Animals; Chronic Pain; Disease Models, Animal; Fibromyalgia; Mice; Pregabalin; Reserpine | 2022 |
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism.
Topics: alpha-Synuclein; Animals; Antioxidants; beta-Cyclodextrins; Disease Models, Animal; Dopaminergic Neu | 2022 |
Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Female; Humans; Male; Motor Activity; Parkinson Disease; | 2022 |
Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease.
Topics: Animals; Disease Models, Animal; Inflammation; Obesity; Oxidative Stress; Parkinson Disease; Reserpi | 2022 |
Broad-spectrum cannabis oil ameliorates reserpine-induced fibromyalgia model in mice.
Topics: Analgesics; Animals; Cannabis; Disease Models, Animal; Dronabinol; Fibromyalgia; Hyperalgesia; Mice; | 2022 |
Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism.
Topics: Aging; Animals; Catalepsy; Disease Models, Animal; Dopamine; Male; Motor Activity; Motor Disorders; | 2022 |
Long-Lasting Nociplastic Pain Modulation by Repeated Administration of Sigma-1 Receptor Antagonist BD1063 in Fibromyalgia-like Mouse Models.
Topics: Analgesics; Animals; Chronic Pain; Disease Models, Animal; Female; Fibromyalgia; Gliosis; Hyperalges | 2022 |
Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
Topics: Acetylcholinesterase; Animals; Disease Models, Animal; Lithium; Male; Neurodegenerative Diseases; Pa | 2023 |
Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans.
Topics: Aged; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditi | 2023 |
Antidepressant effect of 4-Butyl-alpha-agarofuran via HPA axis and serotonin system.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Hypothalamo-Hypophy | 2023 |
Effects of graphene oxide nanoparticles administration against reserpine-induced neurobehavioral damage and oxidative stress in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neurodegenerative D | 2023 |
Repeated reserpine treatment induces depressive-like behaviors accompanied with hippocampal impairment and synapse deficit in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Hippocampus; H | 2023 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
Spontaneous pain-associated facial expression and efficacy of clinically used drugs in the reserpine-induced rat model of fibromyalgia.
Topics: Analgesics; Animals; Disease Models, Animal; Facial Expression; Fibromyalgia; Male; Pain; Rats; Rats | 2019 |
Temporal development of neurochemical and cognitive impairments following reserpine administration in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum; Dis | 2020 |
Antidepressant-like effect of ethanol extract of Blighia unijugata Bak. (Sapindaceae) leaves in acute and chronic models of depression in mice.
Topics: Animals; Blighia; Brain; Depression; Disease Models, Animal; Drug Evaluation, Preclinical; Locomotio | 2019 |
Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model.
Topics: Animals; Benzoquinones; Chitosan; Depression; Disease Models, Animal; Nanoparticles; Polysorbates; R | 2020 |
Relevance of Mitochondrial Dysfunction in the Reserpine-Induced Experimental Fibromyalgia Model.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Fatigue; Fibromyalgia; Male; Mice; Mi | 2020 |
Excessive exercise induces cardiac arrhythmia in a young fibromyalgia mouse model.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Fibromyalgia; Gait; Heart Rate; Male; Mice; M | 2020 |
Phoneutria nigriventer Tx3-3 peptide toxin reduces fibromyalgia symptoms in mice.
Topics: Analgesics; Anesthetics; Animals; Disease Models, Animal; Fibromyalgia; Hyperalgesia; Male; Mice; Ne | 2021 |
Chronic Pregabalin Treatment Ameliorates Pain, but not Depressive-Like Behaviors, in a Reserpine-Induced Myalgia Model in Rats.
Topics: Animals; Anticonvulsants; Antihypertensive Agents; Chronic Pain; Depression; Disease Models, Animal; | 2020 |
Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence.
Topics: Amino Acids; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Cyc | 2021 |
Inhibitors of angiotensin I converting enzyme potentiate fibromyalgia-like pain symptoms via kinin receptors in mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Behavior, Animal; Captopril; Disease Models, Anim | 2021 |
Nociception alterations precede motor symptoms in a progressive model of parkinsonism induced by reserpine in middle-aged rats.
Topics: Animals; Disease Models, Animal; Dorsal Raphe Nucleus; Male; Motor Activity; Nociception; Parkinson | 2021 |
Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Topics: Animals; Disease Models, Animal; Fibromyalgia; Mice; Monoamine Oxidase; Reserpine; Umbelliferones | 2021 |
Effects of intravenous administration of recombinant Phα1β toxin in a mouse model of fibromyalgia.
Topics: Administration, Intravenous; Analgesics; Animals; Disease Models, Animal; Fibromyalgia; Hyperalgesia | 2021 |
Deficiency of Biogenic Amines Modulates the Activity of Hypoglossal Nerve in the Reserpine Model of Parkinson's Disease.
Topics: Animals; Biogenic Amines; Disease Models, Animal; Humans; Hypoglossal Nerve; Male; Parkinson Disease | 2021 |
Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine; Hippocampus; Male; Parkinson Disease | 2021 |
Hesperetin ameliorates electroconvulsive therapy-induced memory impairment through regulation of hippocampal BDNF and oxidative stress in a rat model of depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain-Derived Neurotrophic Factor; Depression; Disease Models | 2021 |
Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Antioxidants; Body Weight; Disease Models, Anim | 2017 |
A standardization of the Novelty-Suppressed Feeding Test protocol in rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Duloxetine | 2017 |
Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models.
Topics: Animals; Antiparkinson Agents; Catalepsy; Cyclohexanols; Disease Models, Animal; Male; Mice; Mice, I | 2017 |
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.
Topics: Animals; Antipsychotic Agents; Blinking; Corpus Striatum; Disease Models, Animal; Dopamine Agents; I | 2018 |
Sleep architecture is altered in the reserpine-induced fibromyalgia model in ovariectomized rats.
Topics: Animals; Disease Models, Animal; Female; Fibromyalgia; Fluoxetine; Hyperalgesia; Ovariectomy; Pain; | 2019 |
Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine.
Topics: Analysis of Variance; Animals; Antiparasitic Agents; Antipsychotic Agents; Catalepsy; Cymenes; Disea | 2018 |
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Caspase 3; Cytokines; Disease Models, Animal; D | 2018 |
An extract of Synedrella nodiflora (L) Gaertn exhibits antidepressant properties through monoaminergic mechanisms.
Topics: Animals; Antidepressive Agents; Asteraceae; Behavior, Animal; Depression; Disease Models, Animal; Fe | 2018 |
α- (phenylselanyl) acetophenone mitigates reserpine-induced pain-depression dyad: Behavioral, biochemical and molecular docking evidences.
Topics: Acetophenones; Analgesics; Animals; Antidepressive Agents; Antioxidants; Brain; Chronic Pain; Depres | 2018 |
Effects of imidazoline I2 receptor agonists on reserpine-induced hyperalgesia and depressive-like behavior in rats.
Topics: Analgesics; Animals; Benzofurans; Depression; Disease Models, Animal; Fibromyalgia; Hyperalgesia; Id | 2019 |
BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Hi | 2019 |
Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism.
Topics: Animals; Anxiety; Brain; CA1 Region, Hippocampal; Cognition; Corpus Striatum; Disease Models, Animal | 2019 |
Sex differences in the progressive model of parkinsonism induced by reserpine in rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Male; Motor Ac | 2019 |
Coexistence of Alterations of Gastrointestinal Function and Mechanical Allodynia in the Reserpine-Induced Animal Model of Fibromyalgia.
Topics: Animals; Body Temperature; Colon; Disease Models, Animal; Feces; Fibromyalgia; Gastric Emptying; Gas | 2019 |
Effects of a rat model of gestational hypothyroidism on forebrain dopaminergic, GABAergic, and serotonergic systems and related behaviors.
Topics: Amygdala; Animals; Anxiety; Anxiety Disorders; Disease Models, Animal; Dopamine; Dopaminergic Neuron | 2019 |
Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia.
Topics: Animals; Brain; Dementia; Disease Models, Animal; Dopamine; Hydroxyindoleacetic Acid; Male; Memory; | 2019 |
Differential impairment of short working and spatial memories in a rat model of progressive Parkinson's disease onset: A focus on the prodromal stage.
Topics: Amygdala; Animals; Astrocytes; Brain; Disease Models, Animal; Hippocampus; Male; Memory Disorders; M | 2019 |
Kinins and their B
Topics: Animals; Behavior, Animal; Bradykinin; Disease Models, Animal; Fibromyalgia; Gene Knockout Technique | 2019 |
Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses.
Topics: Animals; Behavior, Animal; Brain; Coumaric Acids; Depression; Disease Models, Animal; Dopamine; Mice | 2013 |
Neuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apoptosis; Behavior, Animal; Brain Chemistry; Catalepsy; Combined Mod | 2015 |
Effect of Hypericum perforatum on different models of movement disorders in rats.
Topics: Animals; Disease Models, Animal; Fluphenazine; Hypericum; Male; Mastication; Motor Activity; Movemen | 2013 |
Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model.
Topics: Animals; Berberine; Caspase 3; Cerebral Cortex; Depression; Disease Models, Animal; Dopamine; Hippoc | 2013 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Mod | 2013 |
Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dopamine; Hypothalamus; | 2014 |
The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model.
Topics: Animals; Brain; Calcium Channel Blockers; Diclofenac; Disease Models, Animal; Dopamine; Fibromyalgia | 2014 |
Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice.
Topics: Amygdala; Analgesics; Animals; Biogenic Amines; Brain Chemistry; Caspase 3; Chronic Pain; Depression | 2014 |
Female spontaneously hypertensive rats have a compensatory increase in renal regulatory T cells in response to elevations in blood pressure.
Topics: Age Factors; Animals; Antihypertensive Agents; Blood Pressure; Cytokines; Disease Models, Animal; Fe | 2014 |
Evaluation of anti-colitic effect of fluvoxamine against acetic acid-induced colitis in normal and reserpinized depressed rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antipsyc | 2015 |
Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans.
Topics: Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Def | 2016 |
Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats.
Topics: Analgesics; Animals; Brain; Chronic Pain; Disease Models, Animal; Dose-Response Relationship, Drug; | 2015 |
Peripheral and spinal mechanisms of nociception in a rat reserpine-induced pain model.
Topics: Acid Sensing Ion Channels; Action Potentials; Analysis of Variance; Animals; Antihypertensive Agents | 2015 |
(-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
Topics: Animals; Catalase; Catechin; Corpus Striatum; Disease Models, Animal; Glutathione; Lipid Peroxidatio | 2015 |
Magnesium Supplementation Prevents and Reverses Experimentally Induced Movement Disturbances in Rats: Biochemical and Behavioral Parameters.
Topics: Animals; Brain; Disease Models, Animal; Erythrocytes; Lipid Peroxidation; Magnesium; Male; Movement | 2015 |
Sleep restores behavioral plasticity to Drosophila mutants.
Topics: Adenylyl Cyclases; Alzheimer Disease; Animals; Animals, Genetically Modified; Behavior, Animal; Dise | 2015 |
In vivo imaging of CREB phosphorylation in awake-mouse brain.
Topics: Animals; Behavior, Animal; Brain; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Depr | 2015 |
Depressive-like symptoms in a reserpine-induced model of fibromyalgia in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Depression; Disease Models, Animal; Exploratory Behavior; Fee | 2015 |
Breathing in Parkinsonism in the Rat.
Topics: alpha-Methyltyrosine; Animals; Brain; Carotid Body; Disease Models, Animal; Dopamine; Dopamine Agoni | 2016 |
Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Arterioles; Bloo | 2016 |
Echinocystic acid reduces reserpine-induced pain/depression dyad in mice.
Topics: Analgesics; Animals; Behavior, Animal; Brain; Depression; Depressive Disorder; Disease Models, Anima | 2016 |
Nitric oxide pathway activity modulation alters the protective effects of (-)Epigallocatechin-3-gallate on reserpine-induced impairment in rats.
Topics: Animals; Arginine; Catechin; Discrimination, Psychological; Disease Models, Animal; Dose-Response Re | 2016 |
Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats.
Topics: Adenine; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models | 2016 |
Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors.
Topics: Agmatine; Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Do | 2016 |
Transcranial low-level infrared laser irradiation ameliorates depression induced by reserpine in rats.
Topics: Animals; Behavior, Animal; Brain; Depression; Disease Models, Animal; Electroencephalography; Infrar | 2016 |
Effect of N1-dansylspermine and Ro25,6981 on locomotor activity in naive mice and in the reserpinized mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Dansyl Compounds; Disease Models, Animal; Dose- | 2016 |
Functional MRI of the Reserpine-Induced Putative Rat Model of Fibromyalgia Reveals Discriminatory Patterns of Functional Augmentation to Acute Nociceptive Stimuli.
Topics: Animals; Biogenic Amines; Brain; Brain Mapping; Disease Models, Animal; Electric Stimulation; Fibrom | 2017 |
Cannabis exacerbates depressive symptoms in rat model induced by reserpine.
Topics: Acetylcholinesterase; Animals; Cannabis; Cerebral Cortex; Depression; Disease Models, Animal; Dopami | 2017 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
Antidepressant-like effect of ethanol extract from Paeonia lactiflora in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Blepharoptosis; Clomipramine; Depression; Dise | 2008 |
On the mechanism of antidepressant-like action of berberine chloride.
Topics: Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Berberine; Body Temperature; Brain; De | 2008 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
Antidepressant-like effect of peony glycosides in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blepharoptosis; Cerebrum; Depression; Disease Mode | 2008 |
Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity.
Topics: Animals; Clorgyline; Cytosol; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Mem | 2009 |
Re: The neuroprotective effect of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage (Cosar et al. Surg Neurol 2009;71:54-59).
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Dexmedetomidine; Disease Models, Animal | 2009 |
Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia.
Topics: Adrenergic Uptake Inhibitors; Animals; Biogenic Amines; Central Nervous System; Depressive Disorder; | 2009 |
Is it possible to develop an animal model of fibromyalgia?
Topics: Adrenergic Uptake Inhibitors; Animals; Biogenic Amines; Disease Models, Animal; Fibromyalgia; Humans | 2009 |
Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Hi | 2009 |
[Effects of Sijunzi Decoction on urine's xylose excretion rate and ATP in mucosa of spleen deficiency rats].
Topics: Adenosine Triphosphate; Animals; Disease Models, Animal; Drugs, Chinese Herbal; Intestinal Absorptio | 2009 |
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; CHO Cells; Cricetinae; Cricetulus; Disease Models, An | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Antiulcerogenic activity of ethanolic leaf extract of Lasianthera africana.
Topics: Animals; Anti-Ulcer Agents; Disease Models, Animal; Indomethacin; Magnoliopsida; Phytotherapy; Plant | 2009 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxyla | 2010 |
Antidepressant-like effect of genipin in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Blepharoptosis; Depression; D | 2010 |
Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats.
Topics: Animals; Catalepsy; Dietary Supplements; Disease Models, Animal; Fish Oils; Male; Movement Disorders | 2011 |
Evaluation of antidepressant activity of 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-YL)-cyclohexanol, a β-substituted phenylethylamine in mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Beha | 2011 |
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Cells, Cultured; Cholinergic Agents; Corpus Striatum; Dendrit | 2011 |
Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Topics: Animals; Basal Ganglia Diseases; Carya; Catalepsy; Disease Models, Animal; Haloperidol; Male; Moveme | 2011 |
Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Male; Masti | 2011 |
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacterial | 2011 |
Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - an investigation using behavioral tests battery of depression.
Topics: 5-Hydroxytryptophan; Acetamides; Animals; Antidepressive Agents; Behavior; Depression; Disease Model | 2011 |
Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitator | 2012 |
Nicotine restores monoamine neurotransmitter changes in the cortex and hippocampus of reserpinized rats as a model of depression.
Topics: Animals; Antidepressive Agents; Cerebral Cortex; Depression; Disease Models, Animal; Dopamine; Hippo | 2011 |
Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats.
Topics: Animals; Chronic Pain; Constriction; Disease Models, Animal; Fibromyalgia; Hyperalgesia; Male; Neura | 2012 |
Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Biomarkers; Catalepsy; Dis | 2011 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucos | 2012 |
Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Avoidance Learning; Behavior, Animal; Disease Models, Animal; | 2012 |
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion.
Topics: alpha-Methyltyrosine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Down-Regulati | 2012 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
The involvement of noradrenergic mechanisms in the suppressive effects of diazepam on the hypothalamic-pituitary-adrenal axis activity in female rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Neurons; Adrenocorticotropic Hormone; alpha-Meth | 2012 |
[Effect of sijunzi decoction on salivary amylase secretion disorder and VIP-cAMP signaling pathway in splenasthenic rats].
Topics: Amylases; Animals; Cyclic AMP; Disease Models, Animal; Drug Combinations; Drugs, Chinese Herbal; Mal | 2012 |
Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats.
Topics: Amitriptyline; Animals; Anti-Ulcer Agents; Antidepressive Agents; Disease Models, Animal; Duloxetine | 2012 |
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antiparkinson Agents; Carbidopa; Catech | 2013 |
Gallic acid decreases vacuous chewing movements induced by reserpine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Antipsychotic Agents; Brain; Disease Models, An | 2013 |
Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Food Preferences; Injections, Intrape | 2002 |
Effects of sea buckthorn (Hippophaë rhamnoides L.) seed and pulp oils on experimental models of gastric ulcer in rats.
Topics: Animals; Cimetidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hippophae; Ma | 2002 |
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Cannabinoid Receptor | 2003 |
Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dyskin | 2003 |
Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Azoles; Corpus Striatum; Disease Models, Animal | 2003 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Effects of valproic acid on an animal model of tardive dyskinesia.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 2003 |
Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia.
Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Benzazepines; Benzofurans; Binding Site | 2003 |
The effects of paroxetine on rat isolated vas deferens.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2003 |
Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.
Topics: Adrenergic Uptake Inhibitors; Aminobutyrates; Animals; Corpus Striatum; Disease Models, Animal; Elec | 2003 |
Analgesia in phasic and tonic pain tests in a pharmacological model of autotomy.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amphetamine; Analgesia; Animals; Behavio | 2002 |
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopa | 2004 |
Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Diseas | 2004 |
Protective effect of bovine milk whey protein concentrate on the ulcerative lesions caused by subcutaneous administration of indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cattle; Cimetidine; Disease Mod | 2004 |
Effects of topiramate on oral dyskinesia induced by reserpine.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relat | 2004 |
Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.
Topics: Age Factors; Aging; Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Benzene Derivativ | 2004 |
Effects of 25 mT static magnetic field on blood pressure in reserpine-induced hypotensive Wistar-Kyoto rats.
Topics: Animals; Behavior, Animal; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Radia | 2005 |
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Dyskines | 2005 |
Antiulcerogenic activity of a crude hydroalcoholic extract and coumarin isolated from Mikania laevigata Schultz Bip.
Topics: Animals; Anti-Ulcer Agents; Anticoagulants; Coumarins; Disease Models, Animal; Dose-Response Relatio | 2005 |
[Study of the effect of exceed critical extracts from Radix Aucklandiae on experimental gastric ulcer model].
Topics: Acetic Acid; Animals; Anti-Ulcer Agents; Disease Models, Animal; Drugs, Chinese Herbal; Gastric Muco | 2005 |
Effects of reserpine on the plus-maze discriminative avoidance task: dissociation between memory and motor impairments.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Avoidance Learning; Discrimination Lear | 2006 |
Differences in the cellular mechanism underlying the effects of amphetamine on prepulse inhibition in apomorphine-susceptible and apomorphine-unsusceptible rats.
Topics: alpha-Methyltyrosine; Amphetamine; Animals; Apomorphine; Brain; Central Nervous System Stimulants; D | 2007 |
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2007 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Anim | 2007 |
Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Hydroxyl Radical; Ile | 2007 |
The sea urchin embryo, an invertebrate model for mammalian developmental neurotoxicity, reveals multiple neurotransmitter mechanisms for effects of chlorpyrifos: therapeutic interventions and a comparison with the monoamine depleter, reserpine.
Topics: Adrenergic Uptake Inhibitors; Animals; Chlorpyrifos; Disease Models, Animal; Dose-Response Relations | 2007 |
The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity.
Topics: Adrenergic Uptake Inhibitors; Amphetamine-Related Disorders; Animals; Body Temperature; Brain; Corpu | 2008 |
Gene expression patterns in brain cortex of three different animal models of depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Inflammatory Agents; Brain Chemistry; Cerebral Cortex; C | 2008 |
Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Brain; Colitis; Depressive Disorder; Disease Models, Animal; Female; | 2008 |
Effects of various pharmacologic agents on allergic inflammation of the eye. The roles of chemical mediators in ocular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Reactions; Aqueous Humor; Arthus Reaction; Disea | 1980 |
Alprazolam in a biochemical model of depression.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepines; Depression; Diazepam; Disease Models, Ani | 1982 |
Involvement of calcium in coronary vasoconstriction due to prolonged hypoxia.
Topics: Adrenergic alpha-Antagonists; Animals; Calcium; Calcium Channel Blockers; Calcium Chloride; Coronary | 1984 |
Pharmacology of new antidepressants.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder; Disease Models, Animal; Dopamine; Humans | 1984 |
Exocrine pancreatic secretion in rats treated with reserpine after stimulation with pilocarpine, dopamine, and caerulein.
Topics: Amylases; Animals; Bicarbonates; Ceruletide; Chlorides; Cystic Fibrosis; Disease Models, Animal; Dop | 1980 |
Effect of reserpine upon the haemodynamic course of recovery following experimental myocardial infarction.
Topics: Animals; Blood Pressure; Cardiac Output; Disease Models, Animal; Dogs; Electrocardiography; Heart; H | 1980 |
The chronically reserpinized rat as a model for cystic fibrosis: alterations in pancreatic enzyme secretion and storage.
Topics: Amylases; Animals; Cholecystokinin; Chymotrypsin; Cystic Fibrosis; Disease Models, Animal; Male; Pan | 1981 |
Effects of procainamide and N-acetylprocainamide on myocardial contractility in ischemic isolated rabbit hearts.
Topics: Acecainide; Animals; Coronary Disease; Disease Models, Animal; Epinephrine; Male; Myocardial Contrac | 1981 |
The behavioral effect of salbutamol (a beta-adrenergic receptor stimulant) on reserpine- and propranolol-treated rats.
Topics: Albuterol; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Propranolol; | 1983 |
Changes in beta adrenergic receptors in submaxillary glands of chronically reserpine- or isoproterenol-treated rats.
Topics: Animals; Cystic Fibrosis; Disease Models, Animal; Feedback; Isoproterenol; Kinetics; Nucleotidases; | 1981 |
Mechanisms of methacholine-induced coronary vasospasm in an experimental model of variant angina in the anesthetized rat.
Topics: Angina Pectoris, Variant; Animals; Atropine; Blood Pressure; Coronary Circulation; Coronary Vasospas | 1984 |
Pulmonary function of the reserpine and isoproterenol models of cystic fibrosis.
Topics: Airway Resistance; Animals; Cystic Fibrosis; Disease Models, Animal; Isoproterenol; Lung Volume Meas | 1984 |
[Gastric mucosal lesions in rats induced by the communication box paradigm: experimental conditions, endoscopic observation, and effect of vagotomy].
Topics: Acute Disease; Animals; Disease Models, Animal; Endoscopy; Gastric Mucosa; Humans; Male; Rats; Reser | 1984 |
[Electroencephalographic characteristics of "reserpine depression" (experimental study)].
Topics: Amygdala; Animals; Caudate Nucleus; Cerebral Cortex; Depressive Disorder; Disease Models, Animal; El | 1984 |
Antiulcer effects of trimipramine using various laboratory models.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Cimetidine; Dibenzazepines; Disease Models, Animal; Humans; Mal | 1984 |
Acute and chronic models for hypersecretion of intestinal mucin.
Topics: Anaphylaxis; Animals; Cholera Toxin; Cystic Fibrosis; Diarrhea; Disease Models, Animal; Glycoprotein | 1984 |
Behavioral correlations of dopamine receptor activation.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Disease Models, A | 1983 |
The chronically reserpinized rat as a model for cystic fibrosis: alterations in the mucus-secreting sublingual gland.
Topics: Animals; Cystic Fibrosis; Disease Models, Animal; Potassium; Rats; Rats, Inbred Strains; Receptors, | 1983 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 1984 |
The chronically isoproterenol-treated rat in the study of cystic fibrosis: X-ray microanalysis of the submandibular gland.
Topics: Animals; Calcium; Cystic Fibrosis; Disease Models, Animal; Drug Interactions; Electron Probe Microan | 1984 |
Clinical and laboratory studies of spleen deficiency.
Topics: Animals; Autonomic Nervous System; Digestive System; Disease Models, Animal; Female; Humans; Medicin | 1982 |
The B-aminopropionitrile-fed turkey: a model for detecting potential drug action on arterial tissue.
Topics: Aminopropionitrile; Animals; Aorta, Abdominal; Aortic Aneurysm; Aortic Diseases; Disease Models, Ani | 1983 |
Altered bicarbonate reabsorption in the pancreas of reserpine-treated rabbits--a model for cystic fibrosis.
Topics: Animals; Bicarbonates; Cystic Fibrosis; Disease Models, Animal; Male; Pancreatic Juice; Rabbits; Res | 1983 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Con | 1982 |
[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
Topics: Adenylyl Cyclases; Animals; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Brain; Catechol O-Methy | 1981 |
Comparative antihypertensive effects of a diuretic, reserpine, and hydralazine in the spontaneously hypertensive rat.
Topics: Animals; Body Weight; Disease Models, Animal; Female; Furosemide; Hydralazine; Hypertension; Intesti | 1981 |
Study of antiulcer activity of aqueous extract of leaves of Pyrenacantha staudtii (family Icacinaceae) using various models of experimental gastric ulcer in rats.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Disease Models, Animal; Female; Indomethacin; Male; Nigeria; Pl | 1981 |
Composition of pulmonary lavage fluid in control and reserpine-treated rats following chronic isoproterenol and pilocarpine administration.
Topics: Animals; Body Fluids; Carbohydrates; Cystic Fibrosis; Disease Models, Animal; Isoproterenol; Lipids; | 1980 |
Effect of (+/-)-verapamil and hydralazine on stress- and chemically-induced gastric ulcers in rats.
Topics: Animals; Disease Models, Animal; Ethanol; Gastric Acid; Gastric Mucins; Hydralazine; Indomethacin; M | 1994 |
Alterations of pancreatic amylase secretion in the reserpinized rat model of cystic fibrosis. Effects of cerulein and EGF.
Topics: Amylases; Animals; Carbachol; Ceruletide; Cystic Fibrosis; Disease Models, Animal; Epidermal Growth | 1994 |
Effect of acute administration of fish oil (omega-3 marine triglyceride) on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Disease Models, Animal; Ethanol; Female; Fish Oils; Gastric Aci | 1995 |
Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity.
Topics: Adenosine; Analysis of Variance; Animals; Arrhythmias, Cardiac; Catecholamines; Digoxin; Disease Mod | 1995 |
The role of alpha-adrenergic mechanisms within the area postrema in dopamine-induced emesis.
Topics: Adrenergic alpha-Antagonists; alpha-Methyltyrosine; Animals; Atropine; Cats; Cerebral Ventricles; Di | 1995 |
Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Disease Models, Animal; Dose-Respon | 1994 |
Aggressive role of vasopressin in development of different gastric lesions in rats.
Topics: Animals; Arginine Vasopressin; Autoradiography; Cold Temperature; Disease Models, Animal; Dose-Respo | 1994 |
Effects of reserpine administration in two models of portal hypertension in rats.
Topics: Animals; Disease Models, Animal; Hemodynamics; Hypertension, Portal; Male; Rats; Rats, Sprague-Dawle | 1993 |
Plasma immunoreactive cationic trypsin(ogen) pattern in reserpinized rat model of cystic fibrosis. Resemblance to humans.
Topics: Analysis of Variance; Animals; Cystic Fibrosis; Disease Models, Animal; Humans; Male; Mice; Pancreat | 1996 |
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzopyrans; Cromakalim; Diazoxide; Disease Mode | 1996 |
Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Biogenic Mono | 1996 |
Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Temperature; Depression; Disease Models, Anim | 1997 |
Effect of amylin in various experimental models of gastric ulcer.
Topics: Amyloid; Animals; Anti-Ulcer Agents; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dose-R | 1997 |
Effects of monosialoganglioside on a new model of tardive dyskinesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Disease Models, Animal; Dysk | 1997 |
Activity of anticancer compounds against Trypanosoma cruzi-infected mice.
Topics: Animals; Antineoplastic Agents; Berberine Alkaloids; Chagas Disease; Cycloheximide; Disease Models, | 1998 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory | 1998 |
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzofurans; | 1999 |
Effects of buspirone on an animal model of tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Buspirone; Disease Models, Animal; Dopamine; Dyskinesia, Drug | 1999 |
Effects of reserpine on expression of the LDL receptor in liver and on plasma and tissue lipids, low density lipoprotein and fibrinogen in rabbits in vivo.
Topics: Animals; Arteriosclerosis; Culture Techniques; Disease Models, Animal; Ethinyl Estradiol; Fibrinogen | 2000 |
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Cannabinoid Receptor Modulators; Cannabinoids; Cerebral Cortex; Corpus Str | 2001 |
Effect of endogenous catecholamine on myocardial stunning in a simulated ischemia model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Carbac | 2001 |
Animal models of tardive dyskinesia--a review.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free Radicals; gamm | 2001 |
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blepharoptosis; Disease Models, Animal; Dopamine A | 2001 |
The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Convulsants; Disease Models, Animal; Drug Synergism; Dyskines | 2002 |
Behavioral effects of MK-801 on reserpine-treated mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hipp | 2002 |
[Experimental ulcer].
Topics: Animals; Caffeine; Cats; Cattle; Chickens; Disease Models, Animal; Dogs; Ducks; Guinea Pigs; Haplorh | 1975 |
Tyrosine hydroxylase activity in the heart of the cardiomyopathic syrian hamster.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Cricetinae; Disease Models, Animal; Female; Heart Failure; | 1977 |
Effects of cimetidine, a histamine H2-receptor antagonist, on various experimental gastric and duodenal ulcers.
Topics: Administration, Oral; Animals; Aspirin; Carbachol; Depression, Chemical; Disease Models, Animal; Duo | 1977 |
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; | 1978 |
A study of psychomotor epilepsy with "kindled" cat preparations.
Topics: Amygdala; Animals; Cats; Disease Models, Animal; Dopamine; Electric Stimulation; Electroencephalogra | 1976 |
Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Blood Cell Count; Blood Platelets; Cats; Cinanserin; Col | 1977 |
The chronically reserpinized rat as a possible model for cystic fibrosis. I. Submaxillary gland morphology and ultrastructure.
Topics: Animals; Body Weight; Cell Nucleus; Cystic Fibrosis; Cytoplasm; Disease Models, Animal; Endoplasmic | 1975 |
Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression.
Topics: Catecholamines; Depression; Disease Models, Animal; History, 20th Century; Humans; Psychopharmacolog | 1978 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; H | 1977 |
Animal model for cystic fibrosis: pulmonary clearance of Staphylococcus aureus in mice treated with reserpine.
Topics: Animals; Cystic Fibrosis; Disease Models, Animal; Female; Lung; Male; Mice; Mice, Inbred BALB C; Res | 1979 |
Pharmacological & biochemical characterization of antiparkinson drugs in reserpinized mice.
Topics: Animals; Antiparkinson Agents; Ataxia; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Ma | 1979 |
The chronically reserpinized rat as a possible model for cystic fibrosis. VII. Alterations in the secretory response to cholecystokinin and to secretin from the pancreas in vivo.
Topics: Amylases; Animals; Cholecystokinin; Cystic Fibrosis; Disease Models, Animal; Electrolytes; Male; Org | 1978 |
[The relationship between the levels of calcium on the stomach wall and in the blood and ulcerogenic effect of phenylbutazone and reserpine in intact, adrenalectomized and vagotomized rats of various age (author's transl)].
Topics: Adrenalectomy; Age Factors; Animals; Calcium; Disease Models, Animal; Gastric Mucosa; Phenylbutazone | 1978 |
Arterial hypertension induced by femoral lengthening. A canine model.
Topics: Anesthesia, Spinal; Animals; Blood Pressure; Bone Lengthening; Disease Models, Animal; Dogs; Femur; | 1978 |
The influence of weather and climate on the incidence of gastric ulcers after reserpine in rats.
Topics: Animals; Climate; Disease Models, Animal; Peptic Ulcer; Rats; Reserpine; Seasons; Temperature; Weath | 1978 |
The influence of exposure to cold on the incidence of gastric ulcers after reserpine in rats.
Topics: Acclimatization; Animals; Cold Temperature; Disease Models, Animal; Female; Hypothermia, Induced; Pe | 1978 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; L | 1975 |
Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta.
Topics: Animals; Aortic Coarctation; Arteriosclerosis; Blood Pressure; Body Weight; Cholesterol, Dietary; Co | 1976 |
Parkinsonism: animal analogues of the human disorder.
Topics: Animals; Butyrophenones; Chlorpromazine; Disease Models, Animal; Haplorhini; Hydroxydopamines; Levod | 1976 |
Therapeutic prevention of ischemia following intraarterial barbiturate injection.
Topics: Angiography; Animals; Barbiturates; Dextrans; Disease Models, Animal; Ear, External; Heparin; Inject | 1977 |
Effect of intracaudate drug injections on the striatal syndrome in reserpinized cats.
Topics: Animals; Apomorphine; Atropine; Cats; Caudate Nucleus; Corpus Striatum; Dextroamphetamine; Disease M | 1977 |
The chronically reserpinized rat as a possible model for cystic fibrosis. VI. Synergistic effects of isoproterenol on Ca++ and protein in the submaxillary gland.
Topics: Animals; Calcium; Cystic Fibrosis; Disease Models, Animal; Drug Synergism; Isoproterenol; Male; Prot | 1977 |
Effect of local application of apomorphine to the corpus striatum and to the nucleus accumbens on the reserpine-induced rigidity in rats.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, | 1977 |
The chronically reserpinized rat as a possible animal model for cystic fibrosis. IV. The protein composition of pulmonary lavage fluid.
Topics: Adult; Animals; Child; Chronic Disease; Cystic Fibrosis; Disease Models, Animal; Glycoproteins; Huma | 1976 |
Hypothesis for rational therapy in acute stroke.
Topics: Acute Disease; Aminophylline; Animals; Cerebrovascular Disorders; Disease Models, Animal; Drug Evalu | 1976 |
The chronically reserpinized rat as a possible model for cystic fibrosis. II. Comparison and cilioinhibitory effects of submaxillary saliva.
Topics: Animals; Biological Assay; Bivalvia; Calcium; Carbohydrates; Cilia; Cystic Fibrosis; Disease Models, | 1975 |
Catecholamine release as mediator of intracellular enzyme activation in ischaemic perfused rat hearts.
Topics: Animals; Catecholamines; Colorimetry; Coronary Disease; Cytoplasm; Depression, Chemical; Disease Mod | 1975 |
Treatment of experimental frostbite with intra-arterial sympathetic blocking drugs.
Topics: Animals; Dextrans; Disease Models, Animal; Female; Frostbite; Hot Temperature; Injections, Intra-Art | 1975 |
Relationship between animal models and clinical parkinsonism.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Diseas | 1975 |
[The antidepressive properties of anaprilin].
Topics: Animals; Antidepressive Agents; Clonidine; Depression; Disease Models, Animal; Dose-Response Relatio | 1992 |
Alterations of amylase secretion in the chronically reserpinized rat: an acetylcholine-mediated phenomenon.
Topics: Acetylcholine; Amylases; Animals; Body Weight; Carbachol; Ceruletide; Cystic Fibrosis; Disease Model | 1991 |
Rat salivary glands as a model for the study of adrenergic receptor modulation.
Topics: Animals; Autonomic Nervous System; Denervation; Dioxanes; Disease Models, Animal; Prazosin; Rats; Re | 1990 |
The role of intraarterial vasodilators in the treatment of inadvertent intraarterial injection injuries.
Topics: Animals; Arteries; Disease Models, Animal; Ear, External; Injections, Intra-Arterial; Necrosis; Rabb | 1990 |
[Experimental stomach-ulcer on pika].
Topics: Animals; Disease Models, Animal; Female; Immersion; Lagomorpha; Male; Rats; Reserpine; Serotonin; St | 1990 |
Effects of malnutrition and chronic reserpine treatment on pancreatic exocrine function.
Topics: Amylases; Animals; Body Weight; Cystic Fibrosis; Disease Models, Animal; Eating; Lipase; Male; Nutri | 1986 |
The role of mast cells in the elicitation of experimental allergic encephalomyelitis.
Topics: Animals; Chromones; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Hyp | 1989 |
Alterations of pancreatic growth and of GP-2 content in the reserpinized rat model of cystic fibrosis.
Topics: Animals; Cystic Fibrosis; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Enzyme P | 1989 |
Light and electron microscopy of the exocrine pancreas in the chronically reserpinized rat.
Topics: Animals; Cystic Fibrosis; Disease Models, Animal; Dose-Response Relationship, Drug; Endoplasmic Reti | 1989 |
Activation of brain function by S-135, a benzodiazepine receptor inverse agonist.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Brain; Cerebral Cortex; Deoxyglucose; Depression | 1988 |
X-ray microanalysis of exocrine glands in animal models for cystic fibrosis.
Topics: Adrenergic beta-Agonists; Animals; Cystic Fibrosis; Cytoplasmic Granules; Disease Models, Animal; El | 1985 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; M | 1987 |
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Topics: Animals; Cerebral Cortex; Clorgyline; Corpus Striatum; Disease Models, Animal; Dopamine; Glutathione | 1989 |
Reserpine treatment increases viscosity of fluid in the epididymis of rats.
Topics: Animals; Body Weight; Cystic Fibrosis; Disease Models, Animal; Epididymis; Male; Organ Size; Protein | 1988 |
Effects of chronically administered antidepressants and electroconvulsive treatment on cerebral neurotransmitter receptors in rodents with 'model depression'.
Topics: Animals; Antidepressive Agents; Brain; Cyclic AMP; Depression; Disease Models, Animal; Electroconvul | 1986 |
Clearance of Pseudomonas aeruginosa in different rat lung models.
Topics: Animals; Disease Models, Animal; Lung; Male; Neutrophils; Pancreatic Elastase; Pseudomonas aeruginos | 1988 |
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain Diseases; Catheterization; Cerebral Ventricles; Disease Models, | 1988 |
The reserpine-treated rat as an experimental animal model for cystic fibrosis: abnormal Cl transport in pancreatic acinar cells.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfo | 1988 |
Changes in glycoconjugates in rat submandibular gland after chronic treatment with reserpine and isoproterenol.
Topics: Animals; Cystic Fibrosis; Cytoplasmic Granules; Disease Models, Animal; Glycoconjugates; Isoproteren | 1988 |
Potentiated 5-hydroxytryptophan induced response suppression in rats following chronic reserpine.
Topics: 5-Hydroxytryptophan; Animals; Depression; Disease Models, Animal; Drug Synergism; Male; Rats; Rats, | 1987 |
Morphological and histochemical changes in intestinal mucosa in the reserpine-treated rat model of cystic fibrosis.
Topics: Animals; Cystic Fibrosis; Disease Models, Animal; Intestinal Mucosa; Intestine, Large; Intestine, Sm | 1987 |
Pharmacologic profile of fezolamine fumarate: a nontricyclic antidepressant in animal models.
Topics: Animals; Antidepressive Agents; Biological Transport; Blepharoptosis; Brain; Depression; Disease Mod | 1987 |
Calcium and cystic fibrosis.
Topics: Animals; Calcium; Cells, Cultured; Cystic Fibrosis; Disease Models, Animal; Electron Probe Microanal | 1986 |
Animal models of myoclonus using 1,2-dihydroxybenzene (catechol) and chloralose.
Topics: Acetylcholine; Animals; Brain; Catecholamines; Catechols; Chemical Phenomena; Chemistry; Chloralose; | 1986 |
Experimental papillary necrosis of the kidney. 3. Effects of reserpine and other pharmacologic agents on the lesion.
Topics: Adenosine Triphosphatases; Animals; Blood Pressure; Bromine; Catecholamines; Chlorpromazine; Colorin | 1972 |
Prostaglandin B2-induced cutaneous vasoconstriction of the canine hind paw.
Topics: Analysis of Variance; Animals; Blood Pressure; Cold Temperature; Denervation; Dilatation; Disease Mo | 1974 |
Reserpine in experimental cerebral edema: further observations.
Topics: Animals; Blood Pressure; Body Temperature; Brain Edema; Brain Injuries; Cerebral Cortex; Cerebral He | 1974 |
Experimental inhibition of serotonin by antibiotic: prevention of cerebral vasospasm.
Topics: Animals; Cerebral Angiography; Disease Models, Animal; Evaluation Studies as Topic; Haplorhini; Isch | 1974 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Fronta | 1974 |
The influence of cinanserin and selected pharmacologic agents on experimental allergic encephalomyelitis (EAE).
Topics: 5-Hydroxytryptophan; Amphetamine; Anilides; Animals; Azathioprine; Body Weight; Chlorpheniramine; Ci | 1971 |
On the mechanism of fever caused by the mucopeptide of group A streptococcus.
Topics: Animals; Bacterial Proteins; Brain; Disease Models, Animal; Fenclonine; Fever; Injections, Intraveno | 1972 |
Effects of oxyfedrine and ouabain on the heart-lung preparation of the dog.
Topics: Amino Alcohols; Animals; Arrhythmias, Cardiac; Cardiac Output; Disease Models, Animal; Dogs; Female; | 1973 |
On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amantadine; Animals; Brain; Brain Chemistry; Dise | 1974 |
Basic concepts underlying recent developments in the field of Parkinson's disease.
Topics: Biogenic Amines; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Humans; Parkinson Disease; P | 1971 |
Toxicity of acids and bases after intraperitoneal injection.
Topics: Acetates; Acids; Alkalies; Analgesics; Anesthetics, Local; Animals; Anti-Bacterial Agents; Body Temp | 1970 |
Proceedings: Ptosis as a model of depression.
Topics: Animals; Antidepressive Agents; Blepharoptosis; Depression; Disease Models, Animal; Humans; Imiprami | 1974 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermi | 1974 |
Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide.
Topics: Animals; Depression; Dihydroxyphenylalanine; Disease Models, Animal; Dose-Response Relationship, Dru | 1973 |
A reproducible model of left ventricular failure in the closed-chest, anesthetized dog.
Topics: Anesthesia; Animals; Aorta; Arteries; Autonomic Nervous System; Blood Pressure; Carbon Dioxide; Card | 1973 |
The effect of reserpine and d,l-propranolol on digitalis-induced arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Autonomic Nervous System; Cardanolides; Disease Models, Animal; Dogs; | 1973 |
Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Blepharoptosis; Brain; | 1973 |
Neuroleptic and non-neuroleptic catalepsy.
Topics: Animals; Aporphines; Basal Ganglia; Butyrophenones; Catalepsy; Caudate Nucleus; Dibenzazepines; Dibe | 1973 |
[The reserpine model of parkinsonism and changes in the metabolism of mediators].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Epinephrine; Male; Norepin | 1973 |
Chapter 29. Anti-norepinephrine therapy against traumatic hemorrhagic necrosis of the spinal cord: preliminary report.
Topics: Animals; Bretylium Compounds; Cats; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Guan | 1973 |
Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi.
Topics: Animals; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Dose | 1974 |
[Dependence of the anti-inflammatory effect of reserpine, caffeine and apomorphine on adrenal medulla in rats].
Topics: Adrenal Medulla; Animals; Anti-Inflammatory Agents; Apomorphine; Caffeine; Catecholamines; Disease M | 1972 |
[Reserpine and the changes in the serum sialic acid level in experimental inflammation].
Topics: Animals; Disease Models, Animal; Glycoproteins; Inflammation; Neuraminic Acids; Rabbits; Reserpine | 1972 |
Experimental graded "pump failure" of the left ventricle.
Topics: Animals; Aorta, Thoracic; Blood Flow Velocity; Blood Pressure; Carbon Dioxide; Cardiac Output; Cardi | 1971 |
2,6-Dichlorobenzylidene amino guanidine acetate (Wy-8678). A new hypotensive agent.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Female; Guanethidine; Guan | 1969 |